#### Check for updates

#### OPEN ACCESS

EDITED BY Sandra G. Velleman, The Ohio State University, United States

REVIEWED BY Kazuyoshi Ukena, Hiroshima University, Japan Miriam Friedman-Einat, Agricultural Research Organization (ARO), Israel

\*CORRESPONDENCE Yajun Wang, cdwyjhk@gmail.com Juan Li, lijuanscuhk@163.com

SPECIALTY SECTION This article was submitted to Avian Physiology, a section of the journal Frontiers in Physiology

RECEIVED 03 August 2022 ACCEPTED 12 October 2022 PUBLISHED 07 November 2022

#### CITATION

Lv C, Zheng H, Jiang B, Ren Q, Zhang J, Zhang X, Li J and Wang Y (2022), Characterization of relaxin 3 and its receptors in chicken: Evidence for relaxin 3 acting as a novel pituitary hormone. *Front. Physiol.* 13:1010851. doi: 10.3389/fphys.2022.1010851

#### COPYRIGHT

© 2022 Lv, Zheng, Jiang, Ren, Zhang, Zhang, Li and Wang. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Characterization of relaxin 3 and its receptors in chicken: Evidence for relaxin 3 acting as a novel pituitary hormone

Can Lv<sup>1</sup>, Huilu Zheng<sup>1</sup>, Biying Jiang<sup>1</sup>, Qin Ren<sup>1</sup>, Jiannan Zhang<sup>1,2,3</sup>, Xin Zhang<sup>3</sup>, Juan Li<sup>1,2,3</sup>\* and Yajun Wang<sup>1,2,3</sup>\*

<sup>1</sup>Key Laboratory of Bio-Resources and Eco-Environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, China, <sup>2</sup>Animal Disease Prevention and Food Safety Key Laboratory of Sichuan Province, College of Life Sciences, Sichuan University, Chengdu, China, <sup>3</sup>Joint Nutrition Center for Animal Feeding of Sichuan University-Shengliyuan Group, Chengdu, China

Mammalian relaxin (RLN) family peptides binding their receptors (RXFPs) play a variety of roles in many physiological processes, such as reproduction, stress, appetite regulation, and energy balance. In birds, although two relaxin family peptides (RLN3 and INSL5) and four receptors (RXFP1, RXFP2, RXFP2-like, and RXFP3) were predicated, their sequence features, signal properties, tissue distribution, and physiological functions remain largely unknown. In this study, using chickens as the experimental model, we cloned the cDNA of the cRLN3 gene and two receptor (cRXFP1 and cRXFP3) genes. Using cell-based luciferase reporter assays, we demonstrate that cRLN3 is able to activate both cRXFP1 and cRXFP3 for downstream signaling. cRXFP1, rather than cRXFP3, is a cognate receptor for cRLN3, which is different from the mammals. Tissue distribution analyses reveal that cRLN3 is highly expressed in the pituitary with lower abundance in the hypothalamus and ovary of female chicken, together with the detection that cRLN3 co-localizes with pituitary hormone genes LHB/ FSHB/GRP/CART and its expression is tightly regulated by hypothalamic factors (GnRH and CRH) and sex steroid hormone (E2). The present study supports that cRLN3 may function as a novel pituitary hormone involving female reproduction.

#### KEYWORDS

chickens, RLN3, RXFP1, RXFP3, pituitary

### Introduction

Relaxin (RLN) was originally named in 1930 for its role in promoting the relaxation of the pubic ligament during pregnancy in mammals (e.g., guinea pigs and rabbits) (Fevold et al., 1930). Later studies report that RLN belongs to the family of peptide hormones that also include insulin and insulin-like growth factors (IGFs). The crystal structure of RLN is similar to that of insulin including the alpha helices of the A- and B-chain which are mutually supported by the two interchain cysteine bridges and one intrachain bridge in the A-chain (Haley et al., 1982; Hudson et al.,

1983; Patil et al., 2017). Increasing evidence shows that RLNs play important roles in many physiological functions, such as promoting pregnancy response, metabolism, stress, and energy balance (van der Westhuizen et al., 2008; Bathgate et al., 2013; Patil et al., 2017). In vertebrates, the relaxin family peptides vary significantly among species due to multiple (2 or 3) rounds of whole genome duplication and gene gain/loss. Till present, a total of seven structurally related peptides, relaxin 1 (RLN1), RLN2, RLN3, insulin-like peptide 3 (INSL3), INSL4, INSL5, and INSL6, have been identified in humans (Patil et al., 2017). Three RLNs (RLN1, RLN2, and RLN3) exist in higher primates (e.g., great apes), while only RLN1 and RLN3 exist in some mammals such as mice and pigs (Wilkinson et al., 2005; Patil et al., 2017). As the main form in the blood circulation and corpus luteum, RLN1 and RLN2 (in higher primates) are collectively referred to as RLN among these species (Bathgate et al., 2013).

As the typical member of the insulin superfamily, the RLNs bind their receptors to play their physiological roles. In mammals, RLN1 and RLN2 bind the relaxin family peptide 1 receptor (RXFP1) for downstream signaling (Bathgate et al., 2013). As their cognate receptor, RXFP1, which is also called the leucine-rich repeat-containing G-protein-coupled receptor 7 (LGR7), is capable of coupling to multiple G-proteins, thus triggering the pathways including cAMP accumulation (Halls et al., 2006; Halls et al., 2007; Halls et al., 2009), ERK1/2 phosphorylation, NO production, and other signaling pathways (Bathgate et al., 2013). In humans, RLN3 mainly binds the relaxin family peptide 3 receptor (RXFP3) for downstream signaling, which is coupled to the Gai/o protein with cAMP level decrease upon ligand binding (Liu et al., 2003b; Liu et al., 2005; Bathgate et al., 2006; van der Westhuizen et al., 2007). In HEK293T cells, RLN3 was also able to activate RXFP1 inducing a dose-dependent increase in cAMP production (Sudo et al., 2003). Till present, INSL3 is reported to bind the relaxin family peptide 2 receptor (RXFP2) for downstream signaling including cAMP level increase and thymidine incorporation (Kumagai et al., 2002; Hsu et al., 2003). However, the cognate receptors for INSL4 and INSL6 remain to be identified (Bathgate et al., 2013).

In the 1980s, two RLN genes, *RLN1* and *RLN2*, were isolated from the human genome (Crawford et al., 1984). Later, the *RLN3* gene was further isolated (Bathgate et al., 2002). Sequence analyses reveal that the *RLN3* gene is the ancestral gene which continually duplicates, thus bringing the enrichment of RLN family peptides in mammals (Wilkinson et al., 2005). In humans, RLN3 is mainly localized within the brain and is involved in physiological roles including stress, motivated behavior, and appetite regulation (Smith et al., 2011; Ryan et al., 2013; McGowan et al., 2014; Smith et al., 2014; Calvez et al., 2016). As the ancestral gene copy, the *RLN3* gene also duplicates in many lower vertebrates including fish (Wilkinson et al., 2005). For example, in teleost fish, two

peptides closely related to relaxin 3, RLN3a and RLN3b, have been identified (Yang et al., 2020).

In chickens, a relaxin-like peptide has been partially purified from the ovaries of actively laying hens by sizeexclusion chromatography (Brackett et al., 1997). In addition, RLN3 is reported to be related to the transformation of brooding and laying eggs (Shen et al., 2016; Ye et al., 2019). In contrast to the detailed and extensive investigation of the RLN3 peptide in mammals, the sequence features, signaling properties, and expression profiles of RLN3 within the avian species remain poorly understood. Therefore, using chicken as an experimental model, our present study aims to 1) identify the complete ORF sequences of RLN3 and its putative receptors: RXFP1 and RXFP3; 2) reveal the signaling properties of RLN3; and 3) explore the tissue distribution and regulation mechanism of RLN3 expression. The results from our study are the first to establish a clear concept that avian RLN3 is a novel pituitary hormone which may be involved in female reproduction.

### Materials and methods

#### Ethics statement

All the animal experiments were conducted in accordance with the Guidelines for Experimental Animals issued by the Ministry of Science and Technology of the People's Republic of China. The experimental protocol was approved by the Animal Ethics Committee of Sichuan University (Chengdu, China).

#### Chemicals, peptides, and primers

All chemicals were purchased from Sigma-Aldrich (St. Louis, MO), and restriction enzymes were purchased from Takara Biotechnology Co., Ltd., (Dalian, China). The recombinant human relaxin 3 (rhRLN3) was purchased from Roche R&D Center (China) Ltd. Chicken gonadotropin-releasing hormone (GnRH, GnRH1 was used in this study) and corticotropin-releasing hormone (CRH) were synthesized using solid-phase Fmoc chemistry (GL Biochem, Shanghai, China). 17β-estradiol (E2) and progesterone (P4) were purchased from Sigma-Aldrich. dihydrotestosterone (DHT) was purchased from Cayman Chemical Company (Ann Arbor, Michigan, United States). In this study, all chickens of the Lohmann Layer strain were purchased from a local commercial company (Chengdu, China). All primers used in this study were synthesized by Youkang Biological Technology Co., Ltd., (Hangzhou, China) and are listed in Table 1.

Gene name	Sense/antisense	Primer sequence (5'-3')	Size (bp)
Primers for construction of	of the expression plasmids		
cRLN3	Sense	CCGGAATTCAACGGAACGGCGACGCGCCAT	621
	Antisense	CCGGAATTCCATGCACAAGTGCAGAGAGG	
cRXFP1	Sense	CCGGAATTCGCTGAAAGACAGATATGACATC	2,317
	Antisense	CCGGAATTCCCCAAACATATTTACGTGTACG	
cRXFP3	Sense	CCGGAATTCAGCATGGGATGGATGAGCTC	1,341
	Antisense	CCGGAATTCGCCATCTCAGTAGTGTTGCT	
Primers for quantitative re	eal-time RT-PCR assay		
cRLN3	Sense	ATTCTTCTCAAGCAGCAAGT	169
	Antisense	TCTTTGAAGTCATCTGCCAT	
cRXFP1	Sense	GCTCCACGCCATCTCAATAA	160
	Antisense	CAGCGATCCCACCAATTGAC	
cRXFP3	Sense	GTTGGCAATCGTGGCTTCTC	135
	Antisense	GTTTGGTACAGACCCAGCCA	
cβ-actin	Sense	CCCAGACATCAGGGTGTGATG	123
	Antisense	GTTGGTGACAATACCGTGTTCAAT	

TABLE 1 Primers used in this study.

### **Total RNA extraction**

In order to explore the expression of *cRLN3* and its receptors in various tissues of chickens, three adult male and three adult female chickens were purchased from local companies. All chickens were sacrificed and the tissues were isolated, including the various brain regions (telencephalon, midbrain, cerebellum, hindbrain, and hypothalamus), pituitary, heart, liver, spleen, lung, kidney, skin, muscle, adrenal gland, pancreas, duodenum, abdominal fat, spinal cord, testis, ovary, infundibulum, isthmus, uterus, and vagina. All tissue samples were stored at -80°C before use. The total RNA was extracted with RNAzol reagent (Molecular Research Center, Cincinnati, OH) according to the manufacturer's instructions and diluted in H<sub>2</sub>O treated with diethylpyrocarbonate (DEPC). Briefly, after precipitating with DEPC-treated ultra-pure water, the RNAzollysed tissues were centrifuged (12,000 rpm, 10 min). BAN solution (4-bromoanisole) was added to purify the RNA and eliminate genomic DNA. Then, an equal volume of cold 100% isopropanol was added. The precipitated pellet was washed three times with 600 µl 75% ethanol and dissolved in 30 µl RNase-free water. The approximate concentration and purity of samples were determined using a OneDrop 1000 spectrophotometer.

# Reverse transcription and quantitative real-time PCR

For reverse transcription, total RNA (2  $\mu$ g) and 0.5  $\mu$ g of oligo-deoxythymidine were mixed in a volume of 5  $\mu$ l, incubated at 70°C for 10 min, and cooled at 4°C for 2 min. Then, the first

strand buffer, 0.5 mM each deoxynucleotide triphosphate (dNTP), and 100 U Moloney murine leukemia virus (MMLV) reverse transcriptase (Takara) were added to the reaction mix in a total volume of 10  $\mu$ l. Reverse transcription (RT) was performed at 42°C for 90 min. After the reaction, the cDNA templates were diluted with MilliQ-H<sub>2</sub>O and stored at -20°C.

According to our previously established method (Liu et al., 2019), quantitative real-time PCR was performed to examine the expression of *RLN3*, *RXFP1*, and *RXFP3* mRNA among chicken tissues. The qPCR primers of chicken *RLN3*, *RXFP1*, and *RXFP3* were designed based on sequences in the GenBank and are listed in Table 1. The primers (10  $\mu$ M), dNTP (10 mM), easy Taq buffer, easy Taq DNA polymerase (TransGen Biotech), Eva Green (Biotium), MilliQ-H<sub>2</sub>O, and templates were mixed in a total volume of 20  $\mu$ l. Then the reaction mix was conducted on the CFX96 Real-Time PCR Detection System (Bio-Rad). The amplification conditions included an initial denaturation for 10 min at 94°C followed by 20 s of denaturation at 94°C, 15 s annealing at 60°C, and 30 s extension at 72°C for 40 cycles.

# Cloning the cDNA of chicken *RLN3* and its receptors (*RXFP1* and *RXFP3*)

According to the GenBank database, a relaxin peptide (RLN3: NM\_001113200.1) and its two putative receptors (RXFP1: XM\_420385.5; RXFP3: XM\_004937174.3) exist in chickens. Based on the predicted cDNAs of these genes, gene-specific primers were designed to amplify the CDS of *cRLN3*, *cRXFP1*, and *cRXFP3* with high-fidelity DNA Taq polymerase (TOYOBO, Japan). Then, these amplified PCR products were inserted into the

pcDNA3.1 (+) expression vector (for functional assays) and sequenced by Youkang Biological Technology Co., Ltd. Finally, the CDS region of each gene was determined by sequencing at least three independent clones.

# Preparation of chicken RLN3 conditioned medium

To verify whether chicken RLN3 is functional, the conditioned medium of cells expressing cRLN3 (cRLN3<sub>cm</sub>) was prepared. In brief, the expression plasmid of cRLN3 (1,000 ng) was transfected into HEK293 cells cultured in a 6-well plate. After 6 h transfection, the culture medium with 15% fetal bovine serum was replaced and continued for 18 h at 37°C with 5% CO<sub>2</sub>. Then, the serum-rich medium was replaced with 600  $\mu$ l of serum-free medium. After 24 h culture, the conditioned medium containing cRLN3 was collected and concentrated by centrifugation in an Amicon Ultra 3K (Millipore, United States) ultrafiltration tube at 4°C, 5,000 g for 30 min, with a final volume of approximately 1/4 of the original. The concentrated medium was used for subsequent functional tests. Using the same approach, the conditioned medium of cells transfected with empty pcDNA3.1 (+) expression plasmid (pcDNA<sub>cm</sub>) was used as a negative control.

# Functional characterization of chicken RLN3 and its receptors (RXFP1 and RXFP3)

According to our previously established methods (Liu et al., 2019; Jiang et al., 2022), two cell-based luciferase reporter systems (pGL3-CRE-luciferase and pGL3-NFAT-RE-luciferase) were used to verify whether cRLN3<sub>cm</sub> is biologically active and capable of activating cRXFP1 and cRXFP3. In brief, HEK293 cells transiently expressing each receptor (cRXFP1 and cRXFP3) were treated with 30  $\mu$ l serum-free medium containing cRLN3<sub>cm</sub> or pcDNA<sub>cm</sub> (0.001–10  $\mu$ l) for 6 h, and the receptor-activated cAMP/PKA pathways and calcium mobilization were then monitored by pGL3-CRE-luciferase and pGL3-NFAT-RE-luciferase reporter systems, respectively. HEK293 cells expressing empty pcDNA3.1 (+) were used as a negative control.

To compare the functional difference between chicken RLN3 and human RLN3, recombinant human RLN3 (rhRLN3,  $10^{-12}$  to  $10^{-7}$  M, 6 h) was used to treat HEK293 cells expressing cRXFP1 or cRXFP3, respectively, and its potency in activating cRXFP1 and cRXFP3 was also evaluated.

# Preparation of the extracellular medium from chicken pituitary cells

To explore whether pituitary cells can secrete RLN3, we collected the extracellular medium of adult female chicken

pituitary cells to detect its activation potential. According to the method provided in the previous article (Sun et al., 2021; Liu et al., 2022), the anterior pituitaries from a laying hen were isolated and further cut into small pieces with clean scissors. After washing with PBS, the cut pieces were then digested with 0.25% trypsin at 37°C for 30 min. The dispersed pituitary cells were cultured in Medium 199 supplemented with 10% fetal bovine serum in a Corning Cell BIND 48-well plate (Corning, Tewksbury, MA) at 37°C with 5% CO<sub>2</sub>. After 18-h culture, the medium was replaced with a serum-free M199 medium. Four hours later, this extracellular medium from chicken pituitary cells was collected and loaded into Amicon Ultra 3K (Millipore, United States) ultrafiltration tubes for concentration by centrifugation at 4°C, 5,000 g, for 15 min, to a final volume of approximately 1/2 of the original. The HEK293 cells expressing cRXFP1 were treated with a 60 µl serum-free medium containing chicken pituitary cell extracellular medium (2  $\times$  10<sup>-3</sup>µl to 2  $\times$  10<sup>1</sup>µl) for 6 h, and then receptor-activated calcium mobilization was monitored by pGL3-NFAT-RE-luciferase reporter systems. HEK293 cells expressing empty pcDNA3.1 (+) were used as a negative control.

### Effects of hypothalamic factors (gonadotropin-releasing hormone/ corticotropin-releasing hormone) and sex hormone (17β-estradiol/progesterone/ dihydrotestosterone) on *cRLN3* expression in cultured chicken pituitary cells

To explore the regulatory effects of GnRH/CRH/E2/ P4 on cRLN3, the anterior pituitaries isolated from 4week-old female chicks were sliced and digested by 0.25% trypsin at 37°C for 20 min. The dispersed pituitary cells were cultured at a density of  $5 \times 10^5$  cells/well in Medium 199 supplemented with 15% fetal bovine serum. Then, the medium was replaced with a serum-free M199 medium and the cells were incubated with GnRH (1–100 nM), CRH (0.1–10 nM), E2 (100 nM), and P4 (100 nM) for different duration times (4 h/24 h). In the present study, the pituitary cells from 4-week-old male chicks were also treated with DHT (100 nM) for 4 h/24 h. The total RNA was then extracted from cultured pituitary cells and the expression of *RLN3* and  $\beta$ -actin mRNA was assayed by qPCR.

#### Data analysis

The luciferase activities of HEK293 cells expressing cRXFP1/ cRXFP3/pcDNA3.1 (+) in the treated group were expressed as a

	Signal peptide	B-chain	<b>**</b>	
chRLN3 1				AADSSQAASNNLLGRFKMQSAVGPEMQRS 101
duRLN3L 1				GEKNLILELEQ 105
moRLN3 1	-MMLG.LLL.SWALLGALGLQ.EARPA.		R.A	FADGE 70
huRLN3 1	-M.RYMDLL.VWVDTGELWEARAA.			FPDAD 71
tuRLN3L 1	LT RVLC.GIAGL.AELGA. SAPDA.A.			
tuRLN3 1	-MQKL.L.FGMLLSE.RLE.RNP.		R.AGDL	
xeRLN3L 1	-MQGAAMCTT.LHLLEMSRS -MQRVAPALLVVLW.LAWHSGTQ.TSRVPT			<pre>PHWGRG. TM.DSL.EEMNQL.LLPLS.SRVEQL.NA 112EALEVGEPAEVF 71</pre>
xeRLN3 1 sgRLN3L 1				
SGKTH2T T	. LKLHSVFFHCVGSHCLGARA. GVSK.G. IK	······································	·	
			🚽 A-cha	ain
<b>chRLN3</b> 102	NSFLGLETIKDIYSLN-DYNEYESMADDFKELLRO	LEDAAOGDGGCAGVA-PLGPSSYP	ARYPRRKRE-SLOTACMCCKWCC	KADISTICRV 192
		V		
moRLN3 71	ANTDH.ASELDEAVGSS.WLALTKSPQAFY	GGR.SWQGSP	VV.GS.DVLASSSES	.sos <mark>l</mark> 141
huRLN3 72	ADEDS.AGELDEAMGSS.WLALTKSPQAFY	RGRPSWQGTP	VL.GS.DVLA.SSSS	.ssi 142
<b>tuRLN3L</b> 110	SVPQLFYVP.SS.YV.	V.DKNR.T.L.N.M.SN.F.	VKDF.M.VV	<b>L</b> 200
tuRLN3 73	S.EWDASR.PGTLPHQDLSSD.HERWRGKPG.G			
	DFPKDS.NAYDQD.LP.TSNYV.			
xeRLN3 72				
sgRLN3L 99	PLPITQLSVYGV.SDVPLGQ.	VS.LR.QQK-LQTTEKVGNSPHI.	LKS	ND.GRL 189
				×
FIGURE 1				
Amino acid	alignment of chicken RLN3 (chRLN3) \	with that of ducks (duRLN3	L, XP_032061192.1), mice	e (moRLN3, NP_775276.1), humans
(huRLN3 NE	2_543140.1), Western painted turtles (t	URINI XP 005296973 1.	tuRIN3 XP 0053107531	) Xenonus tronicalis (xeRLN3)
		1 5 . 5 .		rved dibasic residues (KR) for proteolytic
processing a	re marked by two arrows. The cysteine	residues of two pairs of dis-	ulfide bonds for A-chain ar	nd B-chain formation are represented
by solid star	s and hollow stars, respectively. The ty	wo cysteine residues used	to form the disulfide bond	d in the A-chain are represented by solid

relative fold increase compared to the control group (without peptide treatment). The relative mRNA levels of target genes were first calculated as the ratios to that of  $\beta$ -actin and then expressed as fold change (or the percentage) compared to their respective controls (chosen tissues). The data were analyzed by Student's t-test (between two groups), or by one-way ANOVA followed by the Dunnett test in GraphPad Prism 7 (GraphPad Software, San Diego, CA). To validate our results, all experiments were repeated twice or thrice.

triangles. Dashes denote gaps in the alignment.

# Results

### Cloning of cRLN3, cRXFP1 and cRXFP3

In this study, the complete ORFs of chicken (c) RLN3, RXFP1, and RXFP3 were cloned for the first time from the chicken brain. The cloned cRLN3 cDNA is 579 bp in length, which encodes a precursor of 192 amino acids (a.a.), with a signal peptide of 22 a.a. located at the N-terminus, followed by the B-chain, C-chain, and A-chain at the C-terminus (Figure 1). Sequence analyses demonstrated that the chicken RLN3 precursor showed a very low sequence identity (28% ~41%) with that of humans, mice, Xenopus tropicalis, and spotted gars. However, as shown in Figure 1, the a.a. sequence identity of the mature peptides among the species is very high. For example, the A- and B-chain of chicken RLN3 share 54% and 67% a.a. sequence identity with those of human RLN3, respectively (Table 2). Like human relaxin family peptides, the cRLN3 precursor showed the conserved two pairs of dibasic residues (K61R62 and K166R167) that were essential for proteolytic processing (Bathgate et al., 2002). In addition, similar to the insulin superfamily members, the six cysteine residues in B- and A-chains critical for the formation of the disulfide bonds (Cys43–Cys177; Cys176–Cys181; and Cys55–Cys190) were detected to be conserved among the species. Moreover, a conserved RxxxRxxI/V motif was detected in the B-chain of cRLN3.

In the present study, the coding region of *cRXFP1* is 2,292 bp in length encoding the receptor of 763 a.a.. Sequence analyses revealed that chicken RXFP1 shared high sequence identity with that of ducks (94%), mice (73%), humans (77%), turtles (82%), *X. tropicalis* (65%), and spotted gars (56%) (Figure 2A). As a typical G-protein-coupled receptor, cRXFP1 also showed the seven transmembrane domains (TM) and a highly conserved NSxLNP(L/I)Y motif for G-protein coupling. Like human RXFP1, chicken RXFP1 showed a very large N-terminus, including a unique low-density lipoprotein receptor type A (LDLa) module and the next 10 leucine-rich repeat (LRR) regions connected by a hinge region (Bathgate et al., 2013).

In the present study, the complete ORF of *cRXFP3* is 1,347 bp in length encoding the receptor of 448 a.a.. Sequence analyses revealed that cRXFP3 also showed high a.a. sequence identity with RXFP3 of ducks (92%), mice (59%), humans (58%), turtles (60%), *X. tropicalis* (63%), and spotted gars (66%) (Figure 2B). In the present study, as shown in Figure 2B, the conserved seven transmembrane domains (TM) and a highly conserved NSxLNP(L/I)Y motif for G-protein coupling were also detected to be conserved in cRXFP3. Unlike cRXFP1, chicken RXFP3 showed a relatively short NH<sub>2</sub>-terminal domain.

	hRLN1 A/B (%)	hRLN2 A/B (%)	hRLN3 A/B (%)
cRLN3 A-chain	41.18	38.24	66.70
cRLN3 B-chain	34.62	34.62	53.85

TABLE 2 Amino acid sequence identity of chicken (c) RLN3 A-chain and B-chain with that of human (h) RLN1/2/3.

# Synteny analyses of *cRLN3*, *cRXFP1* and *cRXFP3*

To examine whether chicken *RLN3*, *RXFP1*, and *RXFP3* are orthologous to the genes identified in other vertebrates, synteny analyses were performed by searching their conserved neighboring genes in the genomes of human and other vertebrates, including ducks (*Anas platyrhynchos*), mice (*Mus musculus*), turtles (*Pelodiscus sinensis or Chrysemys picta*), frogs (*X. tropicalis*), and spotted gars (*Lepisosteus oculatus*) (Figure 3). Interestingly, chicken/duck *RLN3* is orthologous to *RLN3* identified in turtles, frogs, and spotted gars, but not orthologous to *RLN3* identified in humans and mice (Figure 3A). In Figures 3B,C, chicken *RXFP1* and *RXFP3* are orthologous to the genes identified in ducks, humans, mice, turtles, and frogs and spotted gars, respectively.

# Functional characterization of cRLN3, cRXFP1 and cRXFP3

To verify whether chicken RLN3 can activate RXFP1 or RXFP3, a cRLN3-conditioned medium (cRLN3<sub>cm</sub>, 0.001–10  $\mu$ l) was used to treat HEK293 cells expressing cRXFP1/cRXFP3. Receptor activation was examined by pGL3-CRE-luciferase and pGL3-NFAT-RE-luciferase reporter systems established in our previous studies (Liu et al., 2019).

As shown in Figure 4A, using a pGL3-CRE-luciferase reporter system, we demonstrated that cRLN3<sub>cm</sub> could stimulate luciferase activity of HEK293 cells expressing cRXFP1 in a dose-dependent manner, while it could inhibit forskolin (2  $\mu$ M, an adenlyate cyclase activator)-induced luciferase activity of HEK293 cells expressing cRXFP3 dose-dependently. The present finding indicated that cRXFP1 was coupled to the Gs-cAMP signaling pathway, while cRXFP3 was coupled to the Gi-cAMP signaling pathway. Moreover, we found that cRLN3<sub>cm</sub> was at least 10-fold more potent in activating cRXFP1 than cRXFP3.

As shown in Figure 4B, using a pGL3-NFAT-RE-luciferase reporter system, cRLN3<sub>cm</sub> could also stimulate the luciferase activity of HEK293 cells expressing cRXFP1 (not cRXFP3) dose-dependently, indicating that cRXFP1 activation may trigger calcium mobilization.

Considering the close structural and evolutionary relationship between chicken RLN3 and human RLN3, we further tested whether recombinant human RLN3 (rhRLN3) could activate cRXFP1 and cRXFP3. As shown in Figure 5A, using a pGL3-CRE-luciferase reporter system, we demonstrated that rhRLN3 could potently stimulate the luciferase activity of HEK293 expressing cRXFP1 with an EC<sub>50</sub> value of 2.68 nM. In addition, rhRLN3 also could inhibit forskolin-stimulated luciferase activities of HEK293 cells expressing cRXFP3 with an EC50 value of 41.55 nM (Table 3). Using a pGL3-NFAT-RE-luciferase reporter system, we demonstrated that rhRLN3 could stimulate luciferase activities of HEK293 cells expressing cRXFP1 (not cRXFP3) with an  $EC_{50}$  value of 21.15 nM (Figure 5B; Table 3). These findings supported that cRLN3 was functionally similar to human RLN3.

# Expression of *cRLN3*, *cRXFP1* and *cRXFP3* in chicken tissues


Using qPCR, we examined the mRNA expression of *cRLN3* in adult chicken tissues. As shown in Figure 6A, chicken *RLN3* was abundantly expressed in the pituitary and had a lower abundance in the tissue hypothalamus and ovary. The expression abundance of *cRLN3* mRNA in chicken pituitary can reach a high level with a TPM value (>2000), similar to the expression of the pituitary hormone genes *LHB/FHB/GRP* (gastrin-releasing peptide)/*CART* (cocaine- and amphetamine-regulated transcript) (data not shown). Moreover, *cRLN3* shows a dimorphic expression pattern with high abundance in female chickens. As shown in Figure 6B, the expression abundance of *cRLN3* in the female pituitary was about 60 times higher than that in the male pituitary. In the female hypothalamus, its *cRLN3* expression abundance was about 10 times higher than that in male chickens.

In the present study, the high abundance of *cRLN3* in the chicken pituitary led us to further investigate its distribution in pituitary cell clusters from a single-cell dataset reported by our research group (Zhang et al., 2021). As shown in Figure 6D, *cRLN3* has been found mainly to localize in the gonadotroph cell clusters of female chickens. In addition to the gonadotroph cell clusters, *cRLN3* also was found to localize within the lactotroph cell clusters and the folliculo-stellate cells.

Α											DLa										
	chRXFP1	1	MTSDWC	FYTEL	TTGTKV	TRDSLE	DPVSRG	SAACPLO	YFPCGNT			DDCGNHZ	DEDNCEI	NNGWST	OFDKHYTT	DKM	SLYAFO	TETPECI	AGAVP	VECKCOGL	114
	duRXFP1		Y.																		
	moRXFP1	1	GPE	.FCIF	IKYF	TLG	AQI	DVS	SM	SR	.LV	7R.	H.G.		L.YFAN	YYL/	A.TNS.E	AE.S'	v.s	MH.L.RD.	109
	huRXFP1	1	GSV	.FYI.	IF.KYF	SHGG	GQI	DVK.S			.L\	/Q.	G		YFAS	YY!	C.Q.P.E	AE	V.S	.Q.L	109
	XeRXFP1	1	c.	Lv.	1F	F.LCTS.	NQD . GHI	EVT				/Q.	G	· · · · · · Q	L. IFAD	INER	Г.РЦВ. l	АS' М. P.S. Т.	VDS T. P	TO L R	20
	sgRXFP1	ī	MQGY . MRSY	VIGI.	.Y.LR.	SLA.FN	IPESI	KSS	I	.v	.L	Q.	EG	PH	LYFGI	LN	NN.G	.RLDK	L.T	GS.R	111
	-		EVFCDAAK			*	LRR	1	*		LRR2		*	LRR	3	*	LI	RR4		*	
	chRXFP1	115	EVFCDAAK	LRDVPI	LVPSNI	TTMSLQ	KNLLRKI	YADVFR	KYQDİ.KN.	LYLQDI	<b>NKIRAVSK</b>	HAFKGLY	NLTKLYL	SNNKITI	LKPRVFE	DLHKLEW	LIIENNF	RINRISPS	STFYG	LKSLILLDM	4 234
	duRXFP1	118	.IV.	A5	315 S S V	.MI	К Р FT T	SK		C N	DHS V		 9	ь. в в в	G			L		E. N VT	237
	huRXFP1	110	.LDETN	A 5	3.S.V	.A	W I	PP.C.K	N.HQK	N	TSI.I	Y	S	.H.RE	G	R	D.H	ILSF		.NVL	229
	tuRXFP1	116	.LDG.N	AS	S.SV	.LV	W.QI	TS.K		N	E	R		.YB	G		<b>K</b>		н.	.NAL	235
	xeRXFP1	21	.LDG	.T.S	SP.V.	.IN	1.M	GP.E.J	IFPRK.	н.	NTV		• • • • • • • •	.H.ET	G	R	K	.T.Y.Q	Q	NV.	140
	SGRAFPI	112	ע. ט. ט.שי. וסו	.QSS DE	3.ST.V	.KI		N	HN.Q				••••	.1	Q.				1A.	vvi	207
	chRXFP1	235	LRI MNNSLAHL	PDKPL	CQYMPR	LNWLDL	EGNHIHH	LRNVTF	ISCSTLT	VLVMR	<b>LKKI</b> QNKISSLN	ENSFSSL	QMLDELD	LASNEI	SLPAYVE	KDLKELS	QLNLSYN	<b>_KK9</b> IPIKKIQI	DQFD	FLTKLKSLS	5 354
	duRXFP1	238	R.					I	FN	<b>I</b>	۹			K	P.I.						. 357
	moRXFP1	230	A.TR.		H	.HF	RN	[ <b>L</b>	NN	E	(NY	.HA.TH.	.K	.G. K	N. PNI.		I	QEV	N	C.A	. 349
	tuRXFP1	230	LR.		H	.HF			V. N	F			.K	.GK	N PLI.			QT	un	1.V Y.LN	355
	xeRXFP1	141	F.ER.	s	н к	F	NVQS	.T.T	A					N.R	AFSPSLM	.GV	I.H.	QA	3	YVI	236
	sgRXFP1	208	LIS	HAI.	E		QS	VG	SNM	LQI	R.SK.Q	.FTP.	.K.G	.SN.R.Ç	TI.PNL.	4NL	I. <u>.</u>	LEF.I	.L.1	м.н	. 327
	chpypp1	255	LRR1	)	FTDIDN	TOUTVE	VVFOVCC		CRDNED				11 Ventuce	ONTENT	MODVIDO		ETMET CC	VI2	VT E17		
	duRXFP1	358	D		.R			IMPRIVA				QRVEV	·····	GNIEVIC	MRF11R3.	INKLAAL		ADCLAGI		IGAE DIKIN	477
	moRXFP1	350	s.	Q	.RI.											М		v		<b>F</b> .	469
	huRXFP1	350	s.	Q	.RM.				• • • • • • •	· · · · <u>·</u> ·			v			Ү.м	I		· · · · ·	GF.	469
	tuRXFP1	356	T.		.R	 T	• • • • • • •	 F		F		•••••	v	• • • • • • •	 T	M	 т		ц.,	• • • • • • • • • • • • • • • • • • •	356
	soRXFP1	328	P. I		.E.K.	.TG		£			· · · · · · · · · · · · · · · · · · ·							v	,	<b>1</b>	372
						т	M3						TM4								
			GEYNKHAQ																		
	huRXFP1	470		E.?	Г		 	F		 	.VR.G		ITI			 		DT.I.A			589
	tuRXFP1	476									ťG	I.	V	Ί	н			.AT.G	3		595
	xeRXFP1	357	EN	A7	ľQ.R			• • • • • •		••••	G	TT.I.	IV	I	.QTH.	<u>.</u>		. P TAA	· · · · · ·	.I	476
	SGRAFPI	3/3	R	5v	/0	M.		• • • • • •	т	 M6	(.T.GQ	.MIV	Lv	TT	M7	*	• • • • • • •	.P.TM.A	v	<b>.</b>	492
	chRXFP1	595	TM: AAFLIIVE	SYGSMI	FYSVHQ	TAIMAT	EIQNHIK	KEMILA	KRFFFIVI	FTDALC	WIPIFIL	KLLSLLQ	VEIPGTI	TSWVVIE	ILPINSA	LNPLLYT	LTTRPFK	EMIHQFW	YNYR	QRRSKRGKG	G 714
	duRXFP1	598	I				R	т									<mark></mark>	v.		<b>s</b>	717
	moRXFP1	590	VI			SSVTV.	KQV.	vv	• • • • • • • •	• • • • •		.F	DS.	• • • • • • •	• • • • • • • •	II	•••••••	L.	н	VDR.E	E 709
	tuRXFP1	596	I		R	<b>T</b>	R			• • • • • •			• • • • • • • •			4	•••••••	RV	к	.GIGS.S	5 715
	xeRXFP1	477	I																		
					I.R		н	<b>T</b>				 	s.	s		<b>I</b>	I	G.I.	SK	IGNRN	1 596
	SGRAFPI	493	VI	 	I.R NIQR	.GTK	H .YSS	T VTI.	· · · · · · · · · · · · · · · · · · ·	s.		.v	S.	s s		I	I	G.I. .TLL.V.	SK N	IGNRN	N 596 N 610
							H .YSS	T VTI.		s.		.v	S.	s s		I I	I	G.I. .TLL.V.	SK N	IGNRN	∛ 596 ∛ 610
	chRXFP1	715	V.I SQKAYGPS	FIWVEN	WPMHE	ITPKLTI	H .YSS KPVLCTD	T VTI.	TTQSTRLI	s	763	.v	S.	s s		I	I	G.I. .TLL.V.	SK N	IGNRN	N 596 N 610
	chRXFP1 duRXFP1 moRXFP1	715 718 710	SQKAYGPS T TA	FIWVEM	WWPMHE: V	ITPKLTI	H .YSS KPVLCTD 	T VTI.	TTQSTRLI	NSYT .L.M	763 766 758	.v	S.	s		I I	I	G.I. .TLL.V.	SK N	IGNRN	1 596 1 610
	chRXFP1 duRXFP1 moRXFP1 huRXFP1	715 718 710 709	SQKAYGPS T TA GT.A	FIWVEN	MWPMHE: V LQ.N LQ.N	ITPKLTI  MSSGFM MP.E.M	H YSS KPVLCTD  GAF D.F.Y	T SSDASV PC.L.L PCEM.L	TTQSTRLI  VSS IS	NSYT .L.M S	763 766 758 757	.v	S.	s s		I I	I	G.I.	SK N	IGNRN	1 596 1 610
	chRXFP1 duRXFP1 moRXFP1 huRXFP1 tuRXFP1	715 718 710 709 716	SQKAYGPS T TA GT.A M	FIWVEM	MWPMHE V LQ.N LQ.N K.N	ITPKLTI  MSSGFM MP.E.M N.TD	H .YSS KPVLCTD GAF D.F.Y AIY	T VTI. SSDASV PC.L.L PCEM.L ET.	TTQSTRLI  VSS IS .IH	NSYT .L.M S S .L.R	763 766 758 757 764	.v	S.	s s		I I	I	G.I. .TLL.V.	SK N	IGNRN	1 596 1 610
	chRXFP1 duRXFP1 moRXFP1 huRXFP1 tuRXFP1 xeRXFP1	715 718 710 709 716 597	SQKAYGPS T TA GT.A	FIWVEM	MWPMHE: V LQ.N LQ.N K.N	ITPKLTI  MSSGFM MP.E.M N.TD MS.EIM	H YSS KPVLCTD GAF D.F.Y AIY G.Y	T SSDASV PC.L.L PCEM.L .ET. EM.	TTQSTRLI VSS IS .IH	NSYT .L.M S S .L.R	763 766 758 757 764 643	.v	S.	s s		I	I	G.I. .TLL.V.	SK N	IGNRN	7 596 7 610
Б	chRXFP1 duRXFP1 moRXFP1 huRXFP1 tuRXFP1 xeRXFP1	715 718 710 709 716 597	SQKAYGPS TA GT.A M M	FIWVEM	MWPMHE: V LQ.N LQ.N K.N	ITPKLTI  MSSGFM MP.E.M N.TD MS.EIM	H YSS KPVLCTD GAF D.F.Y AIY G.Y	T SSDASV PC.L.L PCEM.L .ET. EM.	TTQSTRLI VSS IS .IH	NSYT .L.M S S .L.R	763 766 758 757 764 643	.v	S.	s s		I	I	G.I. .TLL.V.	SK.	IGNRN	7 596 7 610
В	chRXFP1 duRXFP1 moRXFP1 huRXFP1 tuRXFP1 xeRXFP1 sgRXFP1	715 718 710 709 716 597 611	SQKAYGPS TA. G.T.A. HCA. S.T.	FIWVEN	MWPMHE: V LQ.N K.N LQ.N LQ.N	ITPKLTI MSSGFM MP.E.M N.TD. MS.EIM TN.ATS		T VTI. SSSDASV PC.L.L PCEM.L ET EM IP.EMPC	TTQSTRLI VSS. IS IH NVGKSE.I GLLEDSO	NSYT .L.M S .L.R .L.R LPVKT1	763 766 758 757 764 643 UNGT 664	.v	s.	s s	F	I	NLERADO	G.I. .TLL.V.	SK N	IGNRN	66
в	chRXFP1 duRXFP1 moRXFP1 huRXFP1 tuRXFP1 xeRXFP1 sgRXFP1	715 718 710 709 716 597 611	SQKAYGPS 	FIWVEM	MWPMHE: V LQ.N K.N LQ.N LQ.S GMKEGA	ITPKLTI MSSGFM MP.E.M N.TD MS.EIM TN.ATS DQEPWD .G	H. .YSS KPVLCTD GAF .D.F.Y .AIY .G.Y F.DYLAH TPL	T VTI. SSDASV PC.L.L PCEM.L ET EM IP.EMPC	TTQSTRLI VSS. IS IH NVGKSE.I GLLEDSQ .WGAP	-MGNK:	763 766 758 757 764 643 INGT 664 SNVS	.v	S.	s	F	I I LQLFKNL L.I	I	G.I. .TLL.V.	SK N	IGNRN LTN -MQGDSSD	<b>596</b> <b>€10</b> 66 67
в	chRXFP1 duRXFP1 moRXFP1 huRXFP1 tuRXFP1 xeRXFP1 sgRXFP1 chRXFP3 duRXFP3 moRXFP3	715 718 710 709 716 597 611 1 1	SQKAYGPS: T TA GT.A GT.A  HCA  MDELCESGS .G.PR.F .OVASATPA	FIWVEN	MWPMHE: V. LQ.N LQ.N LQ.N LQ.N GMKEGA	ITPKLTI MSSGFM MP.E.M N.TD MS.EIM TN.ATS DQEPWD .G LS.FFA		T 	TTQSTRLI VSS. IS .H NVGKSE.I GLLEDSQ .WGAP DVAN	-MGNK: R	763 766 758 757 643 INGT 664 SNVS ASLO	.v	S. 	s s	F	I LQLFKNL L.I DD.WWE.	I	G.I. .TLL.V.	SK N	IGNRN LTN -MQGDSSD 	66 67 78
в	chRXFP1 duRXFP1 huRXFP1 tuRXFP1 xeRXFP1 sgRXFP1 chRXFP3 duRXFP3 huRXFP3	715 718 710 709 716 597 611 1 1	SQKAYGPS T GT.A GT.A  H.CA  MDELCESGS .G.P.R.E .QVASATPA 	FIWVEN 	MWPMHE: V LQ.N LQ.N LQ.N LQ.N GMKEGA  AAAGDE AAAGDE	ITPKLTI MSSGFM MP.E.M N.TD MS.EIM TN.ATS DQEPWD .G LLS.FFA LLA.LFS	H YSS KPVLCTD GAF D.F.Y AIY G.Y T.DYLAH TPL .A LTP LTP	T SSDASV PC.L.L PCEM.L ET EM P.EMPC	TTQSTRLI VS.S IS HH NVGKSE.I GLLEDSQ W. GAP DVAN DVAN		763 758 758 764 643 INGT 664 SNVS A.A ASLQ	.v	S.	s s	F L	I LQLFKNL L.I 2D.WWE. PD.WWE.	NLERADG 	G.I. .TLL.V.	SK N 266663 265663	-MQGDSSD -MQGDSSD  AEST.TEA AESA.TEA	66 66 67 78 78
в	chRXFP1 duRXFP1 huRXFP1 tuRXFP1 xeRXFP1 sgRXFP1 chRXFP3 duRXFP3 moRXFP3 huRXFP3 tuRXFP3	715 718 710 709 716 597 611 1 1 1 1	SQKAYGPS T TA GT.A   MDELCESGS  	FIWVEN F F T.LD. CSAAT ATMKI EPQSNI 	MWPMHE: V LQ.N LQ.N LQ.N GMKEGA  AAAGDE AAAGDE AAAGDK LQTK.R S.O.AE	ITPKLTI MSSGFM MP.E.M N.TD MS.EIM TN.ATS DQEPWD .G LLS.FFA LLA.LFS WAFIFL OSDLLG	H .YSS KPVLCTD GAF .D.F.Y AIY T.DYLAH TPL A LTP LVP KVSGRT MFP	T SSDASV PC.L.L PCEM.L ET - EM IP.EMPC	TTQSTRLI VS.S.S. IS NVGKSE.I GLLEDSQ W.GAP DVAN DAAN II.DYD. IF.ER-		763 766 758 764 643 UNGT 664 SNVS ASLQ ASLQ Q. KNKKEM .E		S.	S S YASHSRA	F F L AKRCFSS	LQLFKNL II QD.WWE. YSPSRGI DDFI.GF	NLERADG 	G.I. .TLL.V. AAPGHPF 	SK N PGGGGJ PGGGGJ	-MQGDSSD -MQGDSSD  AEST.TEA AESA.TEA -LV.A -IIA	66 67 78 78 108 64
в	chRXFP1 duRXFP1 huRXFP1 tuRXFP1 xeRXFP1 sgRXFP1 chRXFP3 duRXFP3 huRXFP3	715 718 710 709 716 597 611 1 1 1 1 1	SQKAYGPS T GT.A GT.A  H.CA  MDELCESGS .G.P.R.E .QVASATPA 	FIWVEN F F T.LD. CSAAT ATMKI EPQSNI 	MWPMHE: V LQ.N LQ.N LQ.N GMKEGA  AAAGDE AAAGDE AAAGDK LQTK.R S.O.AE	ITPKLTI MSSGFM MP.E.M N.TD MS.EIM TN.ATS DQEPWD .G LLS.FFA LLA.LFS WAFIFL OSDLLG	H .YSS KPVLCTD GAF .D.F.Y AIY T.DYLAH TPL A LTP LVP KVSGRT MFP	T SSDASV PC.L.L PCEM.L ET - EM IP.EMPC	TTQSTRLI VS.S.S. IS NVGKSE.I GLLEDSQ W.GAP DVAN DAAN II.DYD. IF.ER-		763 766 758 764 643 UNGT 664 SNVS ASLQ ASLQ Q. KNKKEM .E		S.	SS	F F L AKRCFSS	LQLFKNL II QD.WWE. YSPSRGI DDFI.GF	NLERADG 	G.I. .TLL.V. AAPGHPF 	SK N PGGGGJ PGGGGJ	-MQGDSSD -MQGDSSD  AEST.TEA AESA.TEA -LV.A -IIA	66 67 78 78 108 64
в	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 sgRXFP1 sgRXFP1 chRXFP3 duRXFP3 tuRXFP3 sgRXFP3	715 718 710 709 716 597 611 1 1 1 1 1	SQKAYGPS TA GT.A GT.A HCA  MDELCESGS .G.PR.F QVASATPA QMADAATI RIGASLPI  V. NLSY  V. FNDSD	FIWVEM 	MWPMHE: LQ.N L	ITPKLTI MSSGFM MP.E.M N.TD MS.EIM TN.ATS' LQCEPWD .G LS.FFA KLA.LFS WAFIFL 2QSDLLG EGDIFG	H YSS KPVLCTD GAF D.F.Y AIY .G.Y TPL .A. .TPL LVP KVSGHR1 MFP MLP	T SSDASV PC.L.L' PCEM.L ET EM IP.EMPC	TTQSTRLI VS.S IS H GLLEDSQ .W.GAP DVAN DVAN II.DYD. LF.ER- VAAYNTS	-MSYT .L.M S .L.R - LPVKTI - MGNK: R - ASGNI GAV.L GAV.L F.F.R F.F.R T <b>M2</b>	763 758 757 757 643 643 643 643 842  2. KNKEM 	.v	S.	S S YASHSRA	F L L AKRCFSS L	LQLFKNL LQLFKNL LQLWWE. 2D.WWE. SPSSRGI 2DFI.GF AD.NI. TM3	NLERADG G. LP. G. LP. A E. DPDK S	G.I. .TLL.V. AAPGHPF APPGHPF	SK N QGGGJ QGGGJ	-MQGDSSD -MQGDSSD  AEST.TEA AESA.TEA -LV.A -IIA -FVG.A	66 67 78 78 108 64 66
в	chRXFP1 duRXFP1 huRXFP1 tuRXFP1 xeRXFP1 sgRXFP1 chRXFP3 moRXFP3 xeRXFP3 sgRXFP3 chRXFP3 chRXFP3	715 718 710 709 716 597 611	SQRAYGPS T.T.A. G.T.A. G.T.A. G.T.A. MDELCESGS G.P.R.F QVASATPA QMADAATI RIGASLPI .VS.NLSY .V.FNDSD VLRIVISLA	FIWVEM 	MWPMHE: V LQ.N. LQ.N. LQ.N. LQ.N. GMKEGA AAAGDE AAAGDE AAAGDE E.QAAL M1 ALGLVG	ITPKLTI MSSGFM MP.E.M N.TD MS.EIM TN.ATS' ADQEPWD .G ILS.FFA XLA.LFS WAFIFL 2QSDLLG LEGDIFG SNLLVLY	. H	T SSDASV PC.L.L' PCEM.L ET P.EM P.EMPC  FYNPTPY	TTQSTRLI 		763 766 757 757 643 NNUS ASLQ 2. KNKKEM .E T.R QFVLTLPF		S.	SS	F L L AKRCFSS L W VSYVTAMN	LQLFKNL LQLFKNL L.L.I 2D.WWE. YSPSRGI 2DFI.GF ADNI. TM3 MYASVFF	NLERADG G. LP. G. LP. G. LP. J. DKS DPDK S TTAMSVJ	G.I. .TLL.V. AAPGHPF APPGHPF	SK N PGGGGJ PGGGGJ SALKN	-MQGDSSD -MQGDSSD  AEST.TEA AESA.TEA -LV.A -FVG.A QG-RGDPL	66 7 78 78 108 64 66 185
в	chRXFP1 duRXFP1 huRXFP1 huRXFP1 xeRXFP1 sgRXFP1 chRXFP3 duRXFP3 weRXFP3 sgRXFP3 chRXFP3 chRXFP3 duRXFP3 duRXFP3	715 718 710 709 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 7 9 7 9 7	SQKAYGPS TA G. T.A HCA S.T. MDELCESGS G.PR.F QMADAATI RIGASLPI .VS.NLSY .V.FNDSD VLRIVISIA	FIWVEM FIWVEM FINIT CSAAT CSAAT CSAAT ATVNKJ ATVNKJ ATVNKJ AATMIKJ FI SOUCH YSVVC	MWPMHE: V LQ.N. LQ.N. LQ.N. LQ.S. GMKEGA AAAGDE AAAGDE AAAGDE AAAGDE COMMERCIAL AAAGDE AAAGDA AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE AAAGDA AAAGDE AAAGDA AAAGDE AAAGDA AAAGDE AAAGDA AAAAGDA AAAGDA AAAAGDA AAAGDA AAAGDA AAAAGDA AAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAAAAAAA	ITPKLTI MSSGFM MP.E.M N.TD S.EIM TN.ATS' LQ2PWD .G LLS.FFA LLA.LFS WAFIFL Q2DLLG LEGDIFG SNLLVLY	. H YSS KPVLCTD GAF D.F.Y AIY .G.Y. TPL .A KVSGHRJ MFP KVSGHRJ MFP KUSGHRJ		TTQSTRLI VS.S IS NVGKSE.] GLLEDSQ WGAP DVAN DAAN II.DYD. LF.ER- VAAYNTS NLFVTSL	NSYT .L.M S .L.R LPVKTI -MGNK:  	763 768 758 757 643 NNGT 664 SNVS ASLQ ASLQ Q. KNKKEM . E T. R QFVLTLPF	.V	HKGCASS	SS.	F L J. J.KRCFFSS L W VSYVTAMN M. S	II.I D.WWE. PD.WWE. YSPSRGI 20FI.GF AD.NI. TM3 MYASVFF	NLERADG G. LP. G. LP. AE. DPDK DPDK	G.I. .TLL.V. AAPGHPE APPGHPE	SK N PGGGGJ GSGGJ SALKN	-MQGDSSD -MQGDSSD  AREST.TEA AESA.TEA AESA.TEA -FVG.A QG-RGDPL R	66 66 67 78 108 64 66 185 186 198
в	chRXFP1 duRXFP1 huRXFP1 huRXFP1 xeRXFP1 sgRXFP1 chRXFP3 duRXFP3 weRXFP3 sgRXFP3 chRXFP3 chRXFP3 duRXFP3 duRXFP3	715 718 710 709 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 7 9 7 9 7	SQKAYGPS TA G. T.A HCA S.T. MDELCESGS G.PR.F QMADAATI RIGASLPI .VS.NLSY .V.FNDSD VLRIVISIA	FIWVEM FIWVEM FINIT CSAAT CSAAT CSAAT ATVNKJ ATVNKJ ATVNKJ AATMIKJ FI SOUCH YSVVC	MWPMHE: V LQ.N. LQ.N. LQ.N. LQ.S. GMKEGA AAAGDE AAAGDE AAAGDE AAAGDE COMMERCIAL AAAGDE AAAGDA AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE AAAGDA AAAGDE AAAGDA AAAGDE AAAGDA AAAGDE AAAGDA AAAAGDA AAAGDA AAAAGDA AAAGDA AAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAGDA AAAAAAAAAA	ITPKLTI MSSGFM MP.E.M N.TD S.EIM TN.ATS' LQ2PWD .G LLS.FFA LLA.LFS WAFIFL Q2DLLG LEGDIFG SNLLVLY	. H YSS KPVLCTD GAF D.F.Y AIY .G.Y. TPL .A KVSGHRJ MFP KVSGHRJ MFP KUSGHRJ		TTQSTRLI VS.S IS NVGKSE.] GLLEDSQ WGAP DVAN DAAN II.DYD. LF.ER- VAAYNTS NLFVTSL	NSYT .L.M S .L.R LPVKTI -MGNK:  	763 768 758 757 643 NNGT 664 SNVS ASLQ ASLQ Q. KNKKEM . E T. R QFVLTLPF	.V	HKGCASS	SS.	F L J. J.KRCFFSS L W VSYVTAMN M. S	II.I D.WWE. PD.WWE. YSPSRGI 20FI.GF AD.NI. TM3 MYASVFF	NLERADG G. LP. G. LP. AE. DPDK DPDK	G.I. .TLL.V. AAPGHPE APPGHPE	SK N PGGGGJ GSGGJ SALKN	-MQGDSSD -MQGDSSD  AREST.TEA AESA.TEA AESA.TEA -FVG.A QG-RGDPL R	66 66 67 78 108 64 66 185 186 198
В	chRXFP1 duRXFP1 huRXFP1 tuRXFP1 tuRXFP1 xeRXFP1 chRXFP3 duRXFP3 moRXFP3 xeRXFP3 chRXFP3 duRXFP3 duRXFP3 duRXFP3 huRXFP3 huRXFP3 huRXFP3	715 718 710 709 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN FIWVEN F T.LD. CSAAT( ATMNKI EPQSNI  T YSVVC.  W W	MWPMHE: VLQ.N LQ.N LQ.N LQ.N GMKEGA AAAGDE AAAGDE AAAGDE AAAGDE E.QAAL M1 ALGLVG A A A	ITPKLTI MSSGFM MP.E.M N.TD MS.EIM TN.ATS: DQEPWD .G LS.FFA LLS.FFA LLS.FFA LLS.FFA GSDLLG JEGDIFG	. H		TTQSTRLI VS.S. IS H NVGKSE.I GLLEDSQ WGAP DVAN DAAN II.DYD. LF.ER- VAAYNTS NLFVTSL  N.	NSYT L.M S L.R L.R L.R L.R- - SSO - SSO - SSO - - - SSO - - - - - - - - - - - - -	763 758 757 764 643 NNGT 664 SNVS A.A ASLQ 2. KNKKEM .E J. R QFVLTLPE	KKTEDK	S. HKGCASS DFNWLFG K.P. K.P. 	SS.	E E E AKRCFSS W /SYVTAMN 	LQLFKNL LQLFKNL LQLWWE. 2D.WWE. 2DFI.GF MUASVFF MYASVFF	I NLERADG G.LP. G.LP. AE. DFDK DFDK ITAMSVI	G.I. .TLL.V. AAPGHPF APPGHPF 	SK N PGGGGJ SGSGJ SALKNG  SS SS SS SS	-MQGDSSD LTN -MQGDSSD  AESJ.TEA AESJ.TEA -LV.A -IIA -FVG.A QG-RGDPL .R RHTRGR RHTRGR	66 67 78 78 108 64 66 185 186 198 198 224
в	chRXFP1 duRXFP1 huRXFP1 tuRXFP1 xeRXFP1 sgRXFP3 duRXFP3 tuRXFP3 tuRXFP3 tuRXFP3 duRXFP3 duRXFP3 duRXFP3 duRXFP3 tuRXFP	715 718 710 700 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS TA GT.A M S.T MDELCESGS G.PR.F.  QVASATPA 	FIWVEN FIWVEN .F .T.LD. CSAAT(  ATVRKA ATMNKJ EPQSNI .I.A: TAALGSI TYSVVC. .W .W	MWPMHE: VLQ.N. LQ.N. LQ.N. LQ.N. GMKEGA AAAGDE AAAGDE AAAGDE C. C. C	ITPKLTI MSSGFM MP.E.M N.TD MS.EIM TN.ATS: LQEPWD .G LS.FFA ULA.LFS WAFIFL QSDLLG .EGDIFG SNLLVLY	. H		TTQSTRLI VS.S.S. IS H NVGKSE.I GLLEDSQ W.GAP DVAN DAAN II.DYD. LF.ER- VAAYNTS NLFVTSL NLFVTSL N N.		763 768 758 758 643 INGT 664 SNVS ASLQ 2. KNKKEM  P.R QFVLTLPP	KKKTEDK	S. HKGCASS DFNWLFG K.P. 	SS.	F L W /SYVTAMN .M. S. .M. S. .CT.	II.I. LQLFKNL L.I.I 2D.WWE. 2DFI.GF AD.NI. TM3 MYASVFF	I NLERADG G. LP. G. LP. G. LP. J. DKS. DPDK DPDK S TTAMSVJ	G.I. TLL.V. AAPGHPE AAPPGHPE AAPYRSVAS H. F.H Y.HL. Y.	SK N PGGGG PGGGG SALKN SA	-MQGDSSD 	66 66 67 78 108 64 66 185 186 198 198 198 224 179
В	chRXFP1 duRXFP1 huRXFP1 tuRXFP1 xeRXFP1 sgRXFP3 duRXFP3 tuRXFP3 tuRXFP3 tuRXFP3 duRXFP3 duRXFP3 duRXFP3 duRXFP3 tuRXFP	715 718 710 700 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN FIWVEN .F .T.LD. CSAAT(  ATVRKA ATMNKJ EPQSNI .I.A: TAALGSI TYSVVC. .W .W	MWPMHE: VLQ.N. LQ.N. LQ.N. LQ.N. GMKEGA AAAGDE AAAGDE AAAGDE C. C. C	ITPKLTI MSSGFM MP.E.M N.TD MS.EIM TN.ATS: LQEPWD .G LS.FFA ULA.LFS WAFIFL QSDLLG .EGDIFG SNLLVLY			TTQSTRLI VS.S.S. IS H NVGKSE.I GLLEDSQ W.GAP DVAN DAAN II.DYD. LF.ER- VAAYNTS NLFVTSL NLFVTSL N N.		763 768 758 758 643 INGT 664 SNVS ASLQ 2. KNKKEM  P.R QFVLTLPP	KKKTEDK	S. HKGCASS DFNWLFG K.P. 	SS.	F L W /SYVTAMN 	LQLFKNL 	I NLERADG G. LP. G. LP. G. LP. J. DKS. DPDK DPDK S TTAMSVJ	G.I. TLL.V. AAPGHPE AAPPGHPE AAPYRSVAS H. F.H Y.HL. Y.	SK N PGGGG PGGGG SALKN SA	-MQGDSSD 	66 66 67 78 108 64 66 185 186 198 198 198 224 179
в	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 tuRXFP1 sgRXFP1 chRXFP3 duRXFP3 tuRXFP3 sgRXFP3 chRXFP3 tuRXFP3 tuRXFP3 tuRXFP3 tuRXFP3 chRXFP3 chRXFP3 chRXFP3 chRXFP3 chRXFP3 chRXFP3	715 718 710 709 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN FIWVEN .F T. LD. .C.SAAT( .S.AATVRK, ATMNK, ATMNK ATMNK FPQSNI, T.T.A MALGSJ T.Y.SVVC. .W. 	MWPMHE: VLQ.N. LQ.N. LQ.N. LQ.N. GMKEGA AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE AAAGDE A. A. A. A. A. 	ITPKLTI MSSGFM MP.E.M N.TD MS.EIM TN.ATS: DQEPWD .G LS.FFA LLS.FFA LLS.FFA UQSDLLG .EGDIFG SNLLVLY         			TTQSTRLI VS.S. IB. 	NSYT 	763 766 758 764 643 INGT 664 SNVS A.A ASLQ ASLQ ASLQ QFVLTLPH 	.V KKKTEDK WAVENAI	LDFNWLFG K.P. T. S. T. LGLYQTQI	SS.	F L AKRCFSS W /SYVTAMN .M. S. .M. S. .CT.	LQLFKNL LQLFKNL LQLFKNL LL.I 2D.WWE. 2D.WWE. 2DFI.GF 2DFI.GF AD.NI. TM3 WYASVFF	I NLERADG G.LP. G.LP. AE. DKS DPDK I.TAMSVJ	G.I. .TLL.V. ARYRSVAS ARYRSVAS 	S.KN N PGGGG GSGG GSGG GSGG GSGG SALKN SS SS SS SS SS SS SS SS SS	-MQGDSSD 	<ul> <li>596</li> <li>666</li> <li>67</li> <li>78</li> <li>108</li> <li>64</li> <li>66</li> <li>185</li> <li>186</li> <li>198</li> <li>198</li> <li>198</li> <li>129</li> <li>181</li> <li>281</li> </ul>
В	chRXFP1 duRXFP1 mcRXFP1 huRXFP1 sqRXFP1 sqRXFP1 chRXFP3 duRXFP3 duRXFP3 sqRXFP3 duRXFP3 sqRXFP3 chRXFP3 xeRXFP3 xeRXFP3 sqRXFP3 chRXFP3 chRXFP3 chRXFP3	715 718 710 709 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEM FIWVEM FI. CSAAT( CSAAT	MWPMHE:          V          LQ.h          L          L          L          L          L          L          LQ.h	ITPKLTI MSSGRAMP.E.M MP.E.M N.TD MS.EIM TN.ATS' LS.FFA LS.FFA LS.FFA LS.FFA LS.FFA STLLVLY SSDLIG EGDIFG SNLLVLY 	. H		TTQSTRLI VS.S. IS	NSYT L.M S S L.R - POVKTI - MGNKK- - RASGN- TSGNJ GAV.L4 - L.S.RN - TSGNJ GAV.L4 - L.L. - L. - L. - L. - - - - - - - - -	763 766 758 758 764 643 SINGT 664 SINVS 2. KIKKEM 2. KIKEM 2. KFPEGQGG: 	.V KKKTEDK WAVENAL	S. HKGCASS DFNWLFG  K.P.  K.P.  S.  LGLYQTQI I. 	SS.	F L W /SYVTAMN .M. S. .M. S. .C. T. Th LPLAIISI	LQLFKNL LQLFKNL 2D.WWE. YSPSRGI 2DFI.GF AD.NI. TM3 MYASVFF 15 CYLLIVI	I NLERADO G. LP. G. LP. DPDK UTAMSVI LTAMSVI RFISEKH	G.I. .TLL.V. AAPGHPE APPGHPE APPGHPE 	S.K N PGGGGJ GSGGG SALKN SA	-MQGDSSD 	<ul> <li>▶ 596</li> <li>▶ 610</li> <li>66</li> <li>67</li> <li>78</li> <li>108</li> <li>64</li> <li>66</li> <li>185</li> <li>186</li> <li>198</li> <li>198</li> <li>198</li> <li>198</li> <li>198</li> <li>198</li> <li>224</li> <li>281</li> <li>282</li> </ul>
В	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 tuRXFP1 sgRXFP1 chRXFP3 duRXFP3 weRXFP3 chRXFP3 chRXFP3 tuRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 duRXFP3 sgRXFP3	715 718 710 709 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN FIWVEN FIWVEN CSAAT CSAAT CSAAT CSAAT FI CSAAT FI CSAAT FI SAALGS T T T TYSVVC W W W W W W W RESCCF	MNPMHE: 	ITPKLTI MSSGFM MP.E.M N.TD. MS.EIM MS.EIM JQQEPWD .G LS.FFA LS.FFA LLS.LFS WAFIFL QSDLLG EGDIFG SNLLVLY  I  CALIWLI 			TTQSTRLI VS.S.S. IB NVGKSE.J GLLEDSQ W.GAP DVAN DAAN II.DYD. LF.ER- VAANNTSL NLFVTSL NLFVTSL NLFVTSL NLFVTSL	S	763 766 758 758 764 643 SNVS ASLQ 2. KNKKEM R. 	KKKTEDK WAVENAI	S. S. 	SS. SS. SKAMCK IT SKAMCK IT KVLLGFV	F L 	I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.	I NLERADG G.LP. G.LP. AE. .DRS DPDK TLTAMSVI T	G.I. .TLL.V. ARPGHPF APPGHPF 	S.K N GGGGG GGGGG GGGGG GGGGG GGGGG GGGGG GGGG	-MQGDSSD 	<ul> <li>596</li> <li>66</li> <li>67</li> <li>78</li> <li>108</li> <li>64</li> <li>66</li> <li>198</li> <li>224</li> <li>179</li> <li>181</li> <li>281</li> <li>281</li> <li>282</li> <li>318</li> </ul>
В	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 sgRXFP1 chRXFP3 duRXFP3 duRXFP3 sgRXFP3 duRXFP3 duRXFP3 duRXFP3 xeRXFP3 sgRXFP3 chRXFP3 chRXFP3 chRXFP3 moRXFP3 moRXFP3	715 718 710 709 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEM	MNPMHE: 	ITPKLTI MSSGFM MP.E.M N.TD. MS.EIM TN.ATS: LS.FFA ULA.LFS WAFIFL SSDLLG EGDIFG SNLLVLY 	H		TTQSTRLI VS.S. IH NVGKSE.I GLLEDSQ WGAP DVAN DAAN II.DYD. LF.ER- VAAYNTS NLFVTSL NLFVTSL TATVFDI 		763 766 758 758 764 643 SNVS A.A.A SSLQ	W.V.V.V.V.V.V.V.V.V.V.V.V.V.V.V.V.V.V.V	LDFNWLFG K.P. K.P. K.P. T. S. T. LGLYQTQI I. HL. HS.	S. S	F L L L 	II.I. J.L.LERNIL J.L.L.I.J. J.D.WWE. J.SFSRGI J.SFSRGI J.SFSRGI J.SF. TM3 TM3 SVFF 55 CYLLLVI	I G. LP G. LP DRS DPDK ITAMSVI  RFISEKH D D ADR ADR ADR ADR	G.I. .TLL.V. ALPGHPE AAPGHPE AAPGHPE AAPGHPE 	S.K N GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	-MQGDSSD -MQGDSSD  REST.TEA RESA.TEA RESA.TEA RESA.TEA RESA.TEA RCALL RESA.TEA	<ul> <li>596</li> <li>66</li> <li>67</li> <li>78</li> <li>108</li> <li>66</li> <li>185</li> <li>186</li> <li>198</li> <li>224</li> <li>198</li> <li>198</li> <li>224</li> <li>198</li> <li>224</li> <li>318</li> <li>315</li> </ul>
В	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 sgRXFP1 chRXFP3 duRXFP3 duRXFP3 sgRXFP3 duRXFP3 duRXFP3 duRXFP3 sgRXFP3 chRXFP3 chRXFP3 chRXFP3 tuRXFP	715 718 710 709 716 797 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN	MYPHHE: V. LQ.N.	ITPKLTI MSSGFM MSSGFM MS.E.M N.TD MS.E.TM MS.E.TM TN.ATS: ADQEPHD CG LLS.FFA CG CALIWLI CALIWLI CALIWLI CALIWLI CALIWLI S.V.W.A L. C.G. S.V.W.A L. C.G. S.V.W.A L. S.Y.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.W.A S.V.V.V.V.V.V.V.V.V.V.V.V.V.V.V.V.V.V.V			TTQSTRLI VS.S. IS. IH NVGKSE.J GLLEDSQ WGAP DVAN DAAN II.DYD. LF.ER- VAAYNTS NLFVTSL NLFVTSL IT.LGE VK.MGG SSB	NSYT I. MSYT I. R S C- C- C- C- C- C- C- C- C- C- C- C- C	763 766 758 758 764 643 SNVS A.A.A SSLQ	V KKKKTEDK WAVENAI S-NAQFW/ WDR. S-NAQFW/ N-ST.	IHKGCASS DFNWLFG K. P. T. S. T. T. LIGLYQTQQ I. HS. A.	SS.		I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.	NLERADC G. LP. A E. DPDK LTAMSVJ XRFISEKH. D. DR. DR. TDR. ADRR. TDR.	G.I. TLL.V. ALPGHPE AAPGHPE AAPGHPE APPGHPE 	S.KNNSS	-MQGDSSD 	<ul> <li>▶ 596</li> <li>▶ 666</li> <li>667</li> <li>78</li> <li>78</li> <li>108</li> <li>664</li> <li>66</li> <li>185</li> <li>186</li> <li>189</li> <li>198</li> <li>124</li> <li>281</li> <li>282</li> <li>318</li> <li>315</li> <li>318</li> <li>315</li> <li>318</li> <li>270</li> </ul>
В	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 sgRXFP1 chRXFP3 duRXFP3 duRXFP3 sgRXFP3 duRXFP3 duRXFP3 duRXFP3 sgRXFP3 chRXFP3 chRXFP3 chRXFP3 tuRXFP	715 718 710 709 716 797 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN	MYPHHE: V. LQ.N.	ITPKLTI MSSGFM MP.E.M. N.TD SG. SG. LS.FFA JODEPHD J.G. S.C. JODEFDD J.G. S.C. JODEFDD J.G. S.C. JODEFDD J.G. S.C. JODEFDD J.G. S.C. JODEFDD J.G. S.C. JODEFDD J.G. S.S. S.S. S.S. S.S. S.S. S.S. S.S. S.S. S.S. S.S. S.S. S.S. S.S. S			TTQSTRLI VS.S. IS. IH NVGKSE.J GLLEDSQ WGAP DVAN DAAN II.DYD. LF.ER- VAAYNTS NLFVTSL NLFVTSL IT.LGE VK.MGG SSB	NSYT I. MSYT I. MSYT S S - CPVKTI - MGNKX- - SGN/LI - TSGN - TSGN - TSGN - TSGN - TSGN - TSGN - L. - L. - L. - L. - L. - - - SGV-LI - - SGV-LI - - SGV-LI - - SGV-LI - - SGV-LI - - SGV-LI - - SGV-LI - - - SGV-LI - - SGV-LI - - - - - SGV-LI - - - - - - - - - - - - - - - - - -	763 766 758 758 764 643 SINUS ASLQ ASLQ ASLQ Q - KNKKEM  C R C R C	.V KKKKTEDX WAVENAI S-NAQFW WDR. N-ST -D	IHKGCASS DFNWLFG K. P. T. S. T. T. LIGLYQTQQ I. HS. A.	SS.		I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.	NLERADC G. LP. A E. DPDK LTAMSVJ XRFISEKH. D. DR. DR. TDR. ADRR. TDR.	G.I. TLL.V. ALPGHPE AAPGHPE AAPGHPE APPGHPE 	S.KNNSS	-MQGDSSD 	<ul> <li>▶ 596</li> <li>▶ 666</li> <li>667</li> <li>78</li> <li>78</li> <li>108</li> <li>664</li> <li>66</li> <li>185</li> <li>186</li> <li>189</li> <li>198</li> <li>124</li> <li>281</li> <li>282</li> <li>318</li> <li>315</li> <li>318</li> <li>315</li> <li>318</li> <li>270</li> </ul>
В	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 tuRXFP1 sgRXFP1 chRXFP3 duRXFP3 tuRXFP3 sgRXFP3 chRXFP3 chRXFP3 tuRXFP3 tuRXFP3 chRXFP3 chRXFP3 tuRXFP3 sgRXFP3 chRXFP3 sgRXFP3 sgRXFP3 sgRXFP3 sgRXFP3	715 718 710 709 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN	MWPMHE:	ITPKLTI MSSGFM MP.E.M. N.TD N.TD. G IS.FTM S.E.M.	. H YSS GAF D. F. Y. AIY T. DJ F. Y. AIY T. DJ F. T. T. DJ F. Y. A X. T. DJ F. Y. MLP KVSGHRI J. V. S. H. A. A.  S. I. A. A.  X. T. T. T. T. T. T. T. T. T. T. T. T. T.		TTQSTRLI VS.S. IS. IH NVGKSE.I GLLEDSQ W. GAP D. VAN D. VAN D. VAN D. VAN D. VAN TI.DYD. IF. ER- VAAYNTS NLFVTSL NLFVTSL IR. LGG VK. MGG VK. MGG SSS S. SNE	NSYT I. M S L. R L. R L. R - NS - NS - NS - - NS - - - - - - - - - - - -	763 766 758 758 764 643 SNVS ASLQ ASLQ Z. KNKEM  RSLQ Z. KNKEM 	V KKKKTEDK S-NAQFW- WAVENAI S-NAQFW- S- S-NAQFW- S- S- S- NA S- S- S- S- S- S- S- S- S- S- S- S- S-	HKGCASS LDFWWLFF K. P. K. P. T. T. T. LGLYQTQJ I. I. HS. A. A. HA.	S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.		I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.	NLERADC G. LP. G. LP. AE. DPDK LTAMSVV X X X X X X X X X X X X X X X X X X	G.I. TLL.V. AAPGHPF APPGHPF APPGHPF G.H. J.HL. Y.HL. Y.HL. Y.HL. Y.HL. Y.HL. Y.HL. Y.H. Y.H	S.K N PGGGGG SGGGGG SSGG SSGG SSG SS SS SS V V SALKN V SI SS SS SS SS SS SS SS SS SS SS SS SS	-MQGDSSD 	<ul> <li>596</li> <li>666</li> <li>667</li> <li>78</li> <li>108</li> <li>64</li> <li>66</li> <li>185</li> <li>186</li> <li>198</li> <li>198</li> <li>224</li> <li>179</li> <li>181</li> <li>281</li> /ul>
В	chRXFP1 duRXFP1 mcRXFP1 tuRXFP1 sgRXFP1 sgRXFP1 chRXFP3 duRXFP3 duRXFP3 sgRXFP3 chRXFP3 chRXFP3 chRXFP3 chRXFP3 chRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP	715 718 710 709 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN FI.V.S. F T.LD. CSAAT' CSAAT' SATWRK, EPQSN T.ATWRK, EPQSN T.ATWRK, EPQSN T.ATWRK, W. W. W. W. W. W. W. W. W. W. W. W. W.	MWPMHE: VLQ.N LQ.N	ITPKLTI MSSGFM MP.E.M. N.TD MS.EIM MS.EIM MS.EIM C.G.  LS.FPAA LS.FPAA LS.FPAA LS.FPAA LS.FPAA USSI SNLUVLY V.V. I.  SSU CCALIWLI  SSU  SV VSV II.  SV V.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV V I.  SV S			TTQSTRLI VS.S.S. IH NVGKSE.J GLLEDSQ W.GAP DVAN DAAN II.DYD. LF.ER- VAAYNTS NLFVTSL NLFVTSL 	NSYT NSYT . L. M . S . L. R . S . L. R . S . L. R . S . S . L. R . S . S	763 766 758 758 764 643 SNVS A.A.A SSLQ A.SLQ A.SLQ P.R P.R P.R QFVLTLPF KFPEGQG. K.F.PEGQG. R. H. DKLLU R. DKLLL R. DKLLL R.1 DKLL R.1 DKLL R.1 DKLL	.V KKKKTEDK WAVENAI S-NAQFW -SROR.N-ST -D TMT7 	HKGCASS DFNMLFC K. P. T. S. T. T. HL. LGLYQTQJ I. HB. A. A. HA. HA.	SS.	F L 	I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.	I NLERADC G.LP AE. DEDK J TLTAMSVJ	G.I. TLL.V. TLL.V. AAPGHPE AAPGHPE AAPGHPE 	SK N GGGGG GGGGG GGGGG GGGGG GGGGG GGGGG GGGG	-MQGDSSD 	<ul> <li>596</li> <li>666</li> <li>667</li> <li>78</li> <li>108</li> <li>664</li> <li>66</li> <li>185</li> <li>186</li> <li>198</li> <li>224</li> <li>179</li> <li>181</li> <li>281</li> <li>2812</li> <li>318</li> <li>315</li> <li>318</li> <li>270</li> <li>272</li> <li>401</li> </ul>
В	chRXFP1 duRXFP1 moRXFP1 kuRXFP1 sqRXFP1 sqRXFP1 chRXFP3 duRXFP3 duRXFP3 sqRXFP3 duRXFP3 duRXFP3 chRXFP3 chRXFP3 chRXFP3 sqRXFP3 sqRXFP3 chRXFP	715 718 710 709 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN FI.V.S. F T.LD. CSAAT' CSAAT' CSAAT' K.ATYRKA EPQSN T. T.ATYRKA RESCOF FOR STATISTICS W. W. W. T. T. T. T. T. T. T. T. T. T. T. T. T.	MWPMHE: V LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. CMKEGA AAAGDE AAAAGDE AAAAAGDE AAAAGDE AAAAGDE AAAAAGDE AAAAGDE AAAAAGDE AAAAAGDE AAAAAGDE AAAAAAAAAA	ITPKLTI MSSGFM MP.E.M. N.TD MS.EIM MS.EIM MS.EIM G LLS.FPAA LLS.FPAA LLS.FPAA UQSDLG G.WAFIFL G.G.MAA L.G. G. AA L. G. G. AA L. G. SV. VV SV. II FFLCWLI			TTQSTRLI VS.S. IS. IH NVGKSE.J GLLEDSQ W.GAP DVAN DAAN II.DYD. IF.ER- VAAYNTS NLFVTSL NLFVTSL IN. ITATVFDI IR.LGG VK.MGG SSS S.SNE LNVVHFSJ  F.A.P.G		763 766 758 758 764 643 SINGT 664 SINUS 2. KINKKEM 	VV.	HKGCASS DFNWLFC K. P. K. P. T. T. T. HL. LGLYQTQJ I. HS. A. HA. HA.	S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.		I.I.I.L.LLLWRITT	I NLERADC G.LP AE DPDK ILTAMSVI ILTAMSVI N. ADRR. TDR. TDR. TDR. SPSLTTM N.	G.I. TLL.V. TLL.V. AAPGHPE AAPGHPE AAPGHPE 	SK N GGGGG GSGGG GSGGG GSGGG GSGGG GSGGG SALKN SS SS SS SS SS SS SS SS SS SS SS SS SS	-MQGDSSD -MQGDSSD  REST.TEA RESA.	<ul> <li>566</li> <li>66</li> <li>67</li> <li>78</li> <li>108</li> <li>64</li> <li>66</li> <li>185</li> <li>186</li> <li>198</li> <li>224</li> <li>118</li> <li>211</li> <li>221</li> <li>224</li> <li>224</li> <li>224</li> <li>2318</li> <li>2318</li> <li>270</li> <li>270</li> <li>270</li> <li>270</li> <li>270</li> <li>401</li> <li>402</li> <li>403</li> </ul>
В	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 tuRXFP1 sgRXFP1 chRXFP3 duRXFP3 weRXFP3 sgRXFP3 chRXFP3 duRXFP3 tuRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 moRXFP3 sgRXFP3 sgRXFP3 sgRXFP3 chRXFP3 moRXFP3 moRXFP3 moRXFP3 moRXFP3 moRXFP3 sgRXFP3 chRXFP3 moRXFP3 sgRXFP3 chRXFP3 chRXFP3 chRXFP3 moRXFP3 sgRXFP3 chRXFP3 chRXFP3 moRXFP3 chRXFP3 chRXFP3 moRXFP3 chRXFP	715 718 716 700 700 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN FIWVEN FILT FILT FILT FILT FILT FILT FILT FILT	MMPMHE: V LQ.1	ITPKLTI MSSGFM MP.E.M. N.TD MS.EIM MS MS MS MS MS MS MS MS MS M	. H YSS GAF GAF GAF GAF AIY T. DYLAH TPL KVSGHRI MFP MLP WFP MLP WFP MLP		TTQSTRLI VS. S. IS. IH. NVGKSE.I GLLEDSQ W. GAP DVAN D VAN II. DYD. LF. ER- VAAXNTS NLFVTSL NLFVTSL N. N. N. S. S. SNE LNVVHFSJ R.			V KKKKTEDK S-NAQFW SWOR. SROR. D. TM7 SVCLAHSI	HKGCASS HKGCASS LDFNWLFF K P. T. T. LGLYQTQI I. I. HA. HA. HA. HA. VSCLNFTI	S. S		I. I	NLERADC GLP GLP DES DPDK	G.I. TLL.V. TLL.V. ALPGHPE APPGHPE APPGHPE APPGHPE APPGHPE ARYRSVAS 	S K N		<ul> <li>▶ 596</li> <li>♦ 66</li> <li>♦ 67</li> <li>♦ 78</li> <li>● 66</li> <li>● 66</li> <li>● 78</li> <li>↑ 78</li> <li>↑ 88</li> <li>● 198</li> <li>● 224</li> <li>■ 231</li> <li>■ 231<!--</th--></li></ul>
В	chRXFP1 duRXFP1 moRXFP1 xeRXFP1 sgRXFP1 chRXFP3 duRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 moRXFP3 duRXFP3 duRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 sgRXFP3 chRXFP3 sgRXFP3 sgRXFP3 chRXFP3 sgRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP	715 718 716 716 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN FIWVEN F.F T.LD. CSAAT' CSAAT' CSAAT' CSAAT' T.I.A AATVRKA AATVRKA MAALGSI T SVVC W W W W W W T.I.A.	MWPMHE: V LQ.NLQ.N LQ.NLQ.N CGMKEGA. AAAGDE AAGGK 2. AAAGCK 2. AAAAGCK 2. AAAAAGCK 2. AAAAGCK 2. AAAAGCK 2. AAAAGCK 2. AAAAGCK 2. AAAAAGCK 2. AAAAGCK 2. AAAAAGCK 2. AAAAAGCK 2. AAAAAGCK 2. AAAAAGCK 2. AAAAAGCK 2. AAAAAGCK 2. AAAAAGCK 2. AAAAAAGCK 2. AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	ITPKLTI MSSGFM MP.E.M.N.TD N.TD ADQEPHD G G LLS.FFA LLA.LFS WARFIFL LLS.FFA LLS.FFA CQEDLIG QEDLIG QEDLIG QEDLIG CQEDLIG CALIWLI S CALIWLI S S V. V. T T FFLCWLI	H		TTQSTRLI VS.S. III			V KKKKTEDK WAVENAI S-NAQFWI D SVCLAHSI SVCLAHSI		S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.	F L 	I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.I.	NLERADC G. LP A E DPDK STAMSVJ LTAMSVJ	G.I. .TLL.V. AAPGHPE AAPGHPE AAPGHPE APPGHPE 	S.K N GGGGG GGGGG GSGGG GSGGG GSGGG GSGGG SALKN SS SS SS SS SS SS SS SS SS SS SS SS SS	-MQGDSSD -MQGDSSD -MQGDSSD -MQGDSSD -MQGDSSD -MGG AESA.TEA ESA.TEA ESA.TEA 	8         596           66         67           78         60           108         64           66         185           198         198           198         198           198         198           1281         2812           2815         318           270         272           401         402           438         438
В	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 tuRXFP1 sgRXFP1 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 tuRXFP3 sgRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 tuRXFP	715 718 716 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN FIWVEN CSAAT( CS	MMPMHE: 	ITPKLTI MSSGFM MP.E.M.N.TD MS.EIM M			TTQSTRLI VS. S. IS. IH. NVGKSE.1 GLLEDSQ W. GAP DVAN DAAN II. DYD. LF. ER- VAAXNTS NLFVTSL NLFVTSL NLFVTSL  N.      	S. S		V KKKKTEDK S-NAQFW SWOR SROR 	HKCCASS HKCCASS LDFNWLFF K. P. T. T. LGLYQTQJ I. I. HA. HA. HA. HA. YSCINFI V. T. L	S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.	F L AKRCFSS 	I. I	NLERADC GLP GLP DPDK LTAMSVI 	G.I. TLL.V	SK N PGGGGG GSGGG GSGGG GSGGG GSGGG GSGGG SALKN SS SS VV SAAA SS SS VV SAAA SS SS VV SAAA SS SS SS VV SAAA SS SS SS VV SAAA SS SS SS SS SS SS SS SS SS SS SS S	-MQGDSSD 	<ul> <li>► 596</li> <li>● 66</li> <li>● 67</li> <li>● 78</li> <li>■ 78</li> <li>● 66</li> <li>● 66</li> <li>● 66</li> <li>● 198</li> <li>● 24</li> <li>● 24</li> <li>● 23</li> <li>● 23</li> <li>■ 23</li> <li>■ 24</li> <li>● 24</li> <li>■ 24</li> <li>■ 25</li> <li>■ 24</li> /ul>
В	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 tuRXFP1 sgRXFP1 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 tuRXFP3 sgRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 tuRXFP	715 718 716 716 597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN FIWVEN CSAAT( CS	MMPMHE: 	ITPKLTI MSSGFM MP.E.M.N.TD MS.EIM M			TTQSTRLI VS. S. IS. IH. NVGKSE.1 GLLEDSQ W. GAP DVAN DAAN II. DYD. LF. ER- VAAXNTS NLFVTSL NLFVTSL NLFVTSL  N.      	S. S		V KKKKTEDK S-NAQFW SWOR SROR 	HKCCASS HKCCASS LDFNWLFF K. P. T. T. LGLYQTQJ I. I. HA. HA. HA. HA. YSCINFI V. T. L	S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.	F L AKRCFSS 	I. I	NLERADC GLP GLP DPDK LTAMSVI 	G.I. TLL.V	SK N PGGGGG GSGGG GSGGG GSGGG GSGGG GSGGG SALKN SS SS VV SAAA SS SS VV SAAA SS SS VV SAAA SS SS SS VV SAAA SS SS SS VV SAAA SS SS SS SS SS SS SS SS SS SS SS S	-MQGDSSD 	<ul> <li>► 596</li> <li>● 66</li> <li>● 67</li> <li>● 78</li> <li>■ 78</li> <li>● 66</li> <li>● 66</li> <li>● 66</li> <li>● 198</li> <li>● 24</li> <li>● 24</li> <li>● 23</li> <li>● 23</li> <li>■ 23</li> <li>■ 24</li> <li>● 24</li> <li>■ 24</li> <li>■ 25</li> <li>■ 24</li> /ul>
В	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 sqRXFP1 sqRXFP1 chRXFP3 duRXFP3 tuRXFP3 sqRXFP3 chRXFP3 chRXFP3 duRXFP3 chRXFP3 duRXFP3 chRXFP3 duRXFP3 sqRXFP3 sqRXFP3 sqRXFP3 sqRXFP3 sqRXFP3 sqRXFP3 sqRXFP3 chRXFP3 sqRXFP3 sqRXFP3 chRXFP3 chRXFP3 sqRXFP3 chRXFP	71577877611 709776 597611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS SQKAYGPS 	FIWVEN FILVEN CSAAT CSAA	MMPMHE: V LQ.1. LQ.1LQ.1. LQ.1.	ITPKLTI MSSGFM MP.E.M. N.TD MS.EIM MS.EIM MS.EIM TN.ATS' ADQEPMD G IL. LIS FFALS I.L. LIS SNLLVLY I.L. G. AS VW.A. I.L. G. AS VW.A. I.L. G. AS VW.A. I.L. SY. V. SY. V. T.T. FFFLCWLI MARKED SCIENCES STATUS SCIENCES STATUS SCIENCES STATUS SCIENCES STATUS SCIENCES STATUS SCIENCES STATUS SCIENCES STATUS SCIENCES STATUS SCIENCES STATUS SCIENCES SCIE			TTQSTRLI VS. S. IS. IH	S. S		V KKKKTEDK S-NAQFW SWOR SROR 	HKCCASS HKCCASS LDFNWLFF K. P. T. T. LGLYQTQJ I. I. HA. HA. HA. HA. YSCINFI V. T. L	S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.	F L AKRCFSS 	I. I	NLERADC GLP GLP DPDK LTAMSVI 	G.I. TLL.V	SK N PGGGGG GSGGG GSGGG GSGGG GSGGG GSGGG SALKN SS SS VV SAAA SS SS VV SAAA SS SS VV SAAA SS SS SS VV SAAA SS SS SS VV SAAA SS SS SS SS SS SS SS SS SS SS SS S	-MQGDSSD 	<ul> <li>► 596</li> <li>● 66</li> <li>● 67</li> <li>● 78</li> <li>■ 78</li> <li>● 66</li> <li>● 66</li> <li>● 66</li> <li>● 198</li> <li>● 24</li> <li>● 24</li> <li>● 23</li> <li>● 23</li> <li>■ 23</li> <li>■ 24</li> <li>● 24</li> <li>■ 24</li> <li>■ 25</li> <li>■ 24</li> /ul>
в	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 tuRXFP1 xeRXFP3 duRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 tuRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 chRXFP3 duRXFP3 chRXFP3 duRXFP3 xeRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP	715778 716 709716 597 61 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN FILVEN CSAAT( CS	MMPMHE:	ITPKLTI MSSGFM MP.E.M.N.TD MS.EIM MS.EIM TN.ATS: JQQEPMD G.G JLS.FFA LLA.LFS SNLLVLY V. I. I. CALIWLI SNLLVLY I. I. FFICWLI MARGENER SV. VY M.A. J. G. AA SV. JI TFFICWLI			TTQSTRLI VS.S.S. IS NVGKSE.J GLLEDSQ W.GAP DVAN DVAN II.DYD. IF.ER- VAAYNTS NLFVTSL NLFVTSL NLFVTSL 			V KKKKTEDK S-NAQFW SWOR SROR 	HKCCASS HKCCASS LDFNWLFF K. P. T. T. LGLYQTQJ I. I. HA. HA. HA. HA. YSCINFI V. T. L	S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.	F L AKRCFSS 	I. I	NLERADC GLP GLP J DKS . DPDK	G.I. TLL.V	SK N PGGGGG GSGGG GSGGG GSGGG GSGGG GSGGG SALKN SS SS VV SAAA SS SS VV SAAA SS SS VV SAAA SS SS SS VV SAAA SS SS SS VV SAAA SS SS SS SS SS SS SS SS SS SS SS S	-MQGDSSD 	<ul> <li>► 596</li> <li>● 66</li> <li>● 67</li> <li>● 78</li> <li>■ 78</li> <li>● 66</li> <li>● 66</li> <li>● 66</li> <li>● 198</li> <li>● 24</li> <li>● 24</li> <li>● 23</li> <li>● 23</li> <li>■ 23</li> <li>■ 24</li> <li>● 24</li> <li>■ 24</li> <li>■ 25</li> <li>■ 24</li> /ul>
В	chRXFP1 duRXFP1 moRXFP1 xeRXFP1 sgRXFP1 sgRXFP1 chRXFP3 duRXFP3 tuXFP3 tuXFP3 sgRXFP3 chRXFP3 duRXFP3 chRXFP3 duRXFP3 chRXFP3 duRXFP3 sgRXFP3 sgRXFP3 sgRXFP3 sgRXFP3 sgRXFP3 sgRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3	715778 7167709 716597 611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS SQKAYGPS 	FIWVEN FILVEN CSAAT CSAAT CATVRKA ATVNKA TI A CSAAT FI CSAAT	MMPMHE: 	ITPKLTI MSSGFM MP.E.M. N.TD MS.EIM MS.EIM TN.ATS' ADQEPMD .G ALS.FFA LIS.FFA LIS.FFA LIS.FFA .CALIWILI   			TTQSTRLI VS. S. IS. IH. NVGKSE.] GLLEDSQ W. GAP D. VAN D. AAN II.DYD. IF. ER- VAAYNTS NLFVTSL NLFVTSL NLFVTSL NLFVTSL K. K. K. SS AV. LPTASGEC A. T. SS AV.	S. S	763           766           758           757           764           643           SNVS           ASLQ           ASLQ           ASLQ           TR           PVLTLPE           WRVFR           QFVLTLPE           VRNKEM           R. DRLLG           R. DRLLG           YNN           QVVLTPF1           A. V           A. V           A. I. V           8           6           2	V KKKKTEDK S-NAQFW SWOR SROR 	HKCCASS HKCCASS LDFNWLFF K. P. T. T. LGLYQTQJ I. I. HA. HA. HA. HA. YSCINFI V. T. L	S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.	F L AKRCFSS 	I. I	NLERADC GLP GLP J DKS . DPDK	G.I. TLL.V	SK N PGGGGG GSGGG GSGGG GSGGG GSGGG GSGGG SALKN SS SS VV SAAA SS SS VV SAAA SS SS VV SAAA SS SS SS VV SAAA SS SS SS VV SAAA SS SS SS SS SS SS SS SS SS SS SS S	-MQGDSSD 	<ul> <li>► 596</li> <li>● 66</li> <li>● 67</li> <li>● 78</li> <li>■ 78</li> <li>● 66</li> <li>● 66</li> <li>● 66</li> <li>● 198</li> <li>● 24</li> <li>● 24</li> <li>● 23</li> <li>● 23</li> <li>■ 23</li> <li>■ 24</li> <li>● 24</li> <li>■ 24</li> <li>■ 25</li> <li>■ 24</li> /ul>
В	chRXFP1 duRXFP1 moRXFP1 tuRXFP1 tuRXFP1 sgRXFP1 chRXFP3 duRXFP3 xeRXFP3 sgRXFP3 chRXFP3 duRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 xeRXFP3 sgRXFP3 sgRXFP3 chRXFP3 xeRXFP3 sgRXFP3 chRXFP3 chRXFP3 chRXFP3 chRXFP3 duRXFP3 chRXFP3 chRXFP3 duRXFP3 tuRXFP3 chRXFP3 duRXFP3 tuRXFP3 chRXFP3 chRXFP3 chRXFP3 tuRXFP3 tuRXFP3 chRXFP3 chRXFP3 tuRXFP3 chRXFP	7155718 7100 709716 659716 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SQKAYGPS 	FIWVEN FILVEN CSAAT CSAAT CATVRK, ATTVRK, ATTVRK, FILS FILS FILS FILS FILS FILS FILS FILS	MMPMHE: V LQ.1	ITPKLTI MSSGFM MP.E.M. N.TD MS.EIM MS MS.EIM MS.EIM MS.EIM MS.EIM MS.EIM MS.EIM MS.EIM MS.EIM MS.EIM MS.EIM	.H., YSS. .YSS., YSS., YSSS., YSSS., YSSS., YSSS., YSSS., YSSS., YSSS,, YSSS,, YSSS.		TTQSTRLI VS. S. II. II. MUGKSE.I GLLEDSQ W. GAP D. VAN D. AAN D. AAN II. DYD. IF. ER- VAAXNTS NLFVTSL NLFVTSL IR. LGG VK. MGG VK. MGG VK. MGG VK. MGG VK. MGG IR. LGG VK. MGG IR. LGG VK. MGG IR. LGG VK. MGG IR. LGG VK. MGG IR. LGG VK. MGG IR. LGG VK. MGG VK.	S. S		V KKKKTEDK S-NAQFW SWOR SROR 	HKCCASS HKCCASS LDFNWLFF K. P. T. T. LGLYQTQJ I. I. HA. HA. HA. HA. YSCINFI V. T. L	S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.	F L AKRCFSS 	I. I	NLERADC GLP GLP J DKS . DPDK	G.I. TLL.V	SK N PGGGGG GSGGG GSGGG GSGGG GSGGG GSGGG SALKN SS SS VV SAAA SS SS VV SAAA SS SS VV SAAA SS SS SS VV SAAA SS SS SS VV SAAA SS SS SS SS SS SS SS SS SS SS SS S	-MQGDSSD 	<ul> <li>► 596</li> <li>● 66</li> <li>● 67</li> <li>● 78</li> <li>■ 78</li> <li>● 66</li> <li>● 66</li> <li>● 66</li> <li>● 198</li> <li>● 24</li> <li>● 24</li> <li>● 23</li> <li>● 23</li> <li>■ 23</li> <li>■ 24</li> <li>● 24</li> <li>■ 24</li> <li>■ 25</li> <li>■ 24</li> /ul>
В	chRXFP1 duRXFP1 moRXFP1 xeRXFP1 sgRXFP1 chRXFP3 duRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 chRXFP3 duRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP	715 718 710 709 716 597 11 11 11 11 11 11 11 11 11 11 11 11 11	SQKAYGPS SQKAYGPS 	FIWVEN FI.V.CSAAT CSAAT ATVRK. ATVRK. ATVRK. ATVRK. ATVRK. M. W. W. W. W. W. W. W. W. W. W. W. W. W.	MMPMHE: V LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. CMKEGA AAAGDE AAA AA C C C C C C C C C C C C C C C C	ITPKLTI MSSGFM MP.E M N.TD ADS.EIM MS.EIM MS.EIM MS.EIM MS.EIM IN.ATS: ADQEPHD G LLS.FFA LLA.LFS MARTEL LLS.FFA LLS.FFA LLS.FFA LLS.FFA COLORED SNLLVLY       			TTQSTRLI VS.S. II. 			V KKKKTEDK S-NAQFW SWOR SROR 	HKCCASS HKCCASS LDFNWLFF K. P. T. T. LGLYQTQJ I. I. HA. HA. HA. HA. YSCINFI V. T. L	S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.	F L AKRCFSS 	I. I	NLERADC GLP GLP J DKS . DPDK	G.I. TLL.V	SK N PGGGGG GSGGG GSGGG GSGGG GSGGG GSGGG SALKN SS SS VV SAAA SS SS VV SAAA SS SS VV SAAA SS SS SS VV SAAA SS SS SS VV SAAA SS SS SS SS SS SS SS SS SS SS SS S	-MQGDSSD 	<ul> <li>► 596</li> <li>● 66</li> <li>● 67</li> <li>● 78</li> <li>■ 78</li> <li>● 66</li> <li>● 66</li> <li>● 66</li> <li>● 198</li> <li>● 24</li> <li>● 24</li> <li>● 23</li> <li>● 23</li> <li>■ 23</li> <li>■ 24</li> <li>● 24</li> <li>■ 24</li> <li>■ 25</li> <li>■ 24</li> /ul>
В	chRXFP1 duRXFP1 moRXFP1 xeRXFP1 sgRXFP1 chRXFP3 duRXFP3 duRXFP3 sgRXFP3 chRXFP3 duRXFP3 chRXFP3 duRXFP3 chRXFP3 duRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP3 chRXFP3 sgRXFP3 chRXFP	715 718 710 709 716 597 11 11 11 11 11 11 11 11 11 11 11 11 11	SQKAYGPS 	FIWVEN FI.V.CSAAT CSAAT ATVRK. ATVRK. ATVRK. ATVRK. ATVRK. M. W. W. W. W. W. W. W. W. W. W. W. W. W.	MMPMHE: V LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. LQ.N. CMKEGA AAAGDE AAA AA C C C C C C C C C C C C C C C C	ITPKLTI MSSGFM MP.E M N.TD ADS.EIM MS.EIM MS.EIM MS.EIM MS.EIM IN.ATS: ADQEPHD G LLS.FFA LLA.LFS MARTEL LLS.FFA LLS.FFA LLS.FFA LLS.FFA COLORED SNLLVLY       			TTQSTRLI VS.S. II. 			V KKKKTEDK S-NAQFW SWOR SROR 	HKCCASS HKCCASS LDFNWLFF K. P. T. T. LGLYQTQJ I. I. HA. HA. HA. HA. YSCINFI V. T. L	S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.	F L AKRCFSS 	I. I	NLERADC GLP GLP J DKS . DPDK	G.I. TLL.V	SK N PGGGGG GSGGG GSGGG GSGGG GSGGG GSGGG SALKN SS SS VV SAAA SS SS VV SAAA SS SS VV SAAA SS SS SS VV SAAA SS SS SS VV SAAA SS SS SS SS SS SS SS SS SS SS SS S	-MQGDSSD 	<ul> <li>► 596</li> <li>● 66</li> <li>● 67</li> <li>● 78</li> <li>■ 78</li> <li>● 66</li> <li>● 66</li> <li>● 66</li> <li>● 198</li> <li>● 24</li> <li>● 24</li> <li>● 23</li> <li>● 23</li> <li>■ 23</li> <li>■ 24</li> <li>● 24</li> <li>■ 24</li> <li>■ 25</li> <li>■ 24</li> /ul>

#### FIGURE 2

Amino acid sequence alignment of chicken RXFP1/3 with that from other species. (A) Amino acid alignment of chicken RXFP1 (chRXFP1) with that of ducks (duRXFP1, XP\_012952098.1), mice (moRXFP1, NP\_997617.1), humans (huRXFP1, NP\_067647.2), Chinese soft-shell turtles (tuRXFP1, XP\_006121928.1), *X. tropicalis* (xeRXFP1, XP\_017951372.1), and spotted gars (sgRXFP1, XP\_015200025.1). (B) Amino acid alignment of chicken RXFP3 (chRXFP3) with that of ducks (duRXFP3, XP\_027302601.1), mice (moRXFP3, NP\_848832.1), humans (huRXFP3, NP\_057652.1), Chinese soft-shell turtles (tuRXFP1, XP\_006116663.1), *X. tropicalis* (xeRXFP3, XP\_002941625.1), and spotted gars (sgRXFP1, XP\_006627308.1). The seven transmembrane domains (TM1-7) are shaded; the highly conserved NSxLNP(L/I)Y motif present in the TM7 is represented by a dashed overline; dots indicate the amino acid; dashes denote gaps in the alignment. For cRXFP1, the unique low-density lipoprotein receptor type A (LDLa) module is represented by a solid overline; the next 10 leucine-rich repeat (LRR) regions are shown in italics and separated by arrows.



In the present study, the expression of *cRXFP1* and *cRXFP3* genes was also investigated in chicken tissues based on qPCR. *cRXFP1* and *cRXFP3* were detected to be widely but differentially expressed among chicken tissues. As shown in Figure 6E, *cRXFP1* was highly expressed in the infundibulum, uterus, hypothalamus, and the varied functional brain areas (except the cerebellum). In contrast, *cRXFP3* was detected to be predominantly expressed in the hypothalamus and kidney with moderate/weak expression among tissues including the spinal cord, hindbrain, and ovary (Figure 6F).

# The signaling of the secreted cRLN3 from chicken pituitary cells

In the present study, in order to explore whether the chicken pituitary can synthesize and secret the biologically active cRLN3 protein, the extracellular medium of adult female chicken pituitary cells was collected to explore its activation potential for cRXFP1. Using the pGL3-NFAT-RE-luciferase reporter system, we found that cRXFP1 could be activated by the culture medium of pituitary cells with luciferase activity increase in HEK293 cells (Figure 6C).


# The regulation of *cRLN3* mRNA expression in cultured pituitary cells

In the present study, the high abundance of *cRLN3* mRNA in the pituitary gland of female chickens led us to further investigate its expression regulation profile. Since *cRLN3* was detected to be localized mainly in the gonadotroph cells, where the GnRHRs and CRHRs were found to be abundantly expressed (Shimizu and Bédécarrats, 2006; Joseph et al., 2009; Zhang et al., 2021), the hypothalamic factors GnRH and CART were employed to investigate their roles in the regulation of *cRLN3* mRNA expression by qPCR. As shown in Figure 7A, the GnRH (10 nM) was able to slightly increase the expression of *cRLN3* mRNA after 4 h of treatment. However, the GnRH (10 nM) was not able to further regulate the expression of *cRLN3* mRNA after 24 h of treatment. In contrast, the CRH was able to significantly increase the expression of *cRLN3* mRNA in a time-dependent manner. In the present study, the different concentrations of the GnRH (1–100 nM, 4 h) and CRH (0.1–10 nM, 24 h) were further employed to examine their effect on the *cRLN3* mRNA expression. As shown in Figures 7B,C, both GnRH and CRH treatments could increase the expression level of *cRLN3* mRNA in a dose-dependent manner, while the stimulation effect of CRH was higher than that of GnRH.

In the present study, the regulatory effects of sex hormones E2 (100 nM), P4 (100 nM), and DHT (100 nM) on the expression of *cRLN3* mRNA in the cultured pituitary cells were also investigated. As shown in Figure 7D, E2 treatment for 4 h could increase the expression level of *cRLN3* mRNA in the cultured pituitary cells. However, the longer E2 treatment (24 h) could not regulate the mRNA expression of *cRLN3*. In the present study, both P4 and DHT treatments could not affect the expression of *cRLN3* mRNA in the cultured pituitary cells.

### Discussion

In the present study, the genes encoding the chicken relaxin 3 peptide (cRLN3) and its two receptors cRXFP1 and cRXFP3 have been cloned for the first time. Functional studies reveal that cRLN3 can activate cRXFP1 and cRXFP3 for downstream signaling. Between the two receptors, cRXFP1 showed a higher




binding potency with cRLN3 than cRXFP3, supporting their differential roles among the tissues. In the cultured pituitary cells, the expression of *cRLN3* mRNA is tightly regulated by the hypothalamic factors GnRH and CRH and sex steroid hormone E2. In combination with the detection that the high abundance of *RLN3* mRNA in the pituitary and its co-localization with pituitary hormones genes *LHB/FSHB/GRP/CART* in gonadotroph cells in a dimorphic pattern, the present study supports that RLN3 is a novel pituitary hormone involving female reproduction in avian species.

# Chicken *RLN3* gene is the duplicated copy of the ancestral *RLN3* gene

In this study, the chicken *RLN3* gene has been cloned for the first time. Sequence analyses reveal that the precursor protein

deduced from cRLN3 shares a low sequence identity with that of other species. However, its A-chain and B-chain from mature proteins still show a higher sequence identity than that of humans, supporting their functional conservation across species (Patil et al., 2017). In addition, the motif RxxxRxxI/V sequences were detected to be conserved in the B-chain, also supporting its function for receptor binding (Bathgate et al., 2013). In the present study, synteny analyses reveal that chicken/ duck RLN3 is orthologous to RLN3 identified in turtles, frogs, and spotted gars, but not orthologous to RLN3 identified in humans and mice (Figure 3A). The present study supports that the isolated relaxin 3 gene is likely to be the duplicated copy (RLN3-L) from the ancestral relaxin 3 gene, which emerged prior to the divergence of fish (Wilkinson et al., 2005; Yegorov and Good, 2012; Yegorov et al., 2014). Thus, among the lower vertebrates, the gene duplication of RLN3-L brings



reporter system (A) or a pGL3-NFAT-RE-luciferase reporter system (B). HEK293 cells transfected with an empty pcDNA3.1 (+) vector were used as a control and rhRLN3 treatment did not change the luciferase activity, indicating the specific action on receptor activation. Each data point represents the mean  $\pm$  SEM of three replicates (N = 3).


TABLE 3 EC<sub>50</sub> values of rhRLN3 in activating different signaling pathways in HEK293 cells expressing chicken (c) RXFP1 and RXFP3.

Signaling pathway	cAMP/PKA (nM)	Ca <sup>2+</sup> (nM)		
cRXFP1	2.68	21.15		
cRXFP3	41.55	_		
		21.15		

*RLN3a* and *RLN3b* reported in teleost fish (Wilkinson et al., 2005; Yegorov et al., 2014). In chicken, the gene duplication of *RLN3-L* brings the *cRLN3* gene reported in the present study and the predicted *cINSL5* gene (Wilkinson et al., 2005). In contrast, the ancestral *RLN3* gene, which disappeared in chicken, further duplicates in mammals, thus bringing the gene cluster where *RLN1*, *RLN2*, and *RLN3* are located among the mammalian species (Good et al., 2012; Bathgate et al., 2018). In vertebrates, genome duplication and gene gain/loss result in the abundance of relaxin family peptides. The isolation and synteny analyses of *cRLN3* in the present study provide a unique clue for the relaxin family members' evolution across species.

In the present study, two RLN3 receptors, *RXFP1* and *RXFP3* also have been cloned in chickens. As shown in Figure 2A, chicken RXFP1 shows a high a.a. sequence identity with that of other species. The cloned cRXFP1 shows a large N-terminal, including an LDLa module that is essential for downstream signaling (Halls et al., 2005; Hopkins et al., 2006; Scott et al., 2006) and an LRR region for ligand binding (Scott et al., 2006). In addition, the cloned cRXFP1 also shows the typical seven transmembrane domains with the conserved site for G-protein coupling (Bathgate et al., 2013). Synteny analyses show that the cloned *cRXFP1* is orthologous to *RXFP1* from other vertebrates including humans (Figure 3B), thus suggesting their conserved downstream signaling.

Similar to cRXFP1 to be conserved among the species, the cloned chicken RXFP3 also shares a high sequence identity with that of other species. Like mammalian RXFP3, chicken RXFP3 also contains a short N-terminus, which is crucial for



(A) Quantitative real-time RT-PCR (qPCR) analysis showing the abundant expression of cRLN3 in various adult chicken tissues. Each data point represents the mean ± SEM of six individual adult chickens (three males and three females) (N = 6). Tc, Telencephalon; Mb, Midbrain; Cb, Cerebellum; Hb, Hindbrain; Hy, Hypothalamus; Pi, Pituitary; He, Heart; Li, Liver; Sp, Spleen; Lu, Lung; Ki, Kidney; Sk, Skin; Mu, Muscle; Ad, Adrenal gland; Pa, Pancreas; Du, Duodenum; Ab, Abdominal fat; Sc, Spinal cord; Te: Testis; Ov, Ovary; In, Infundibulum; Is, Isthmus; Ut, Uterus; Va, Vagina. (B) Quantitative real-time RT-PCR analysis showing the sex-differential expression of cRLN3 in the pituitary and hypothalamus of chickens. Each data (Continued)

#### FIGURE 6 (Continued)

point represents the mean  $\pm$  SEM of three individual adult chickens (three males or three females) (N = 3). (**C**) Effects of the chicken pituitary cell (Pi) extracellular medium ( $1 \times 10^{-3}\mu$ l to  $1 \times 10^{1}\mu$ l extracellular medium in 30  $\mu$ l medium, 6 h) on the activation of cRXFP1 expressed in HEK293 cells, monitored by a pGL3-NFAT-RE-luciferase reporter system. HEK293 cells transfected with an empty pcDNA3.1 (+) vector were used as a control and Pi extracellular medium treatment did not change the luciferase activity, indicating the specific action on receptor activation. Each data point represents the mean  $\pm$  SEM of three replicates (N = 3). (**D**) Chicken pituitary single-cell transcriptome data (at https://scrna.avianscu.com/pit/) showing that *cRLN3* is highly expressed in female chicken pituitary gonadotrophs. (d1) Uniform Manifold Approximation and Projection (UMAP) map showing the identified eight pituitary cell clusters. Cells are colored by Seurat clustering and annotated by cell clusters (each point represents a single cell). Gona, gonadotrophs; Lac, lactotrophs; Cort, corticotrophs; Thy, thyrotrophs; FS, folliculo-stellate cells; Endo, endothelial cells; WBC, white blood cells; (d2) UMAP map showing the expression of *cRLN3* in distinct cell clusters of the female chicken pituitary. The overall expression level of *cRLN3* was high in all pituitary cell clusters of the male chicken pituitary. In the male chicken pituitary, *cRLN3* was only very poorly expressed in the criticary, *cRLN3* was only very poorly expressed in the criticary, *cRLN3* was only very poorly expressed in the criticary of *cRLN7* [1] and *cRXFP1* [2] and *cRXFP3* [F] in various adult chicken tissues. Each data point represents the mean  $\pm$  SEM of ix individual adult chickens (three males and three females) (N = 6).

ligand binding and signal transduction (Bathgate et al., 2013). In the present study, the seven transmembrane domains and the conserved site for G-protein coupling also have been detected in chicken RXFP3, supporting it to be the typical G-protein-coupled receptor. Synteny analysis shows that the cloned *cRXFP3* is orthologous to that of other vertebrates including humans, supporting their conserved evolution profile.

# Chicken RLN3 binds cRXFP1 and cRXFP3 for downstream signaling

In the present study, the chicken RLN3-conditioned medium (cRLN3<sub>cm</sub>) could activate cRXFP1 expressed in HEK293 cells, thus stimulating the Gs-cAMP/PKA signaling pathway. Our finding is consistent with the reports in mammals that RXFP1 can be activated by RLN3 (Sudo et al., 2003; Halls et al., 2006). However, only a dose-dependent increase in luciferase activity in HEK293 cells expressing chicken cRXFP1 is detected in the present study which is different from the report in mammalian species that RXFP1 is capable of coupling to Gs and other G-proteins (Gi/o), thus showing a biphasic pattern of cAMP accumulation (Halls et al., 2006; Halls et al., 2007).

In the present study, the chicken RLN3-conditioned medium (cRLN3<sub>cm</sub>) can also activate cRXFP3 through the inhibition of forskolin-stimulated luciferase activity, indicating that cRXFP3 is functionally coupled to the Gi protein (Figure 4A). The present finding is consistent with the findings in mammals (Kocan et al., 2014). In humans, the activation of RXFP3 inhibits forskolin-stimulated cAMP accumulation in a variety of cell lines (Liu et al., 2003b; Liu et al., 2005; van der Westhuizen et al., 2010). The present study supports conserved downstream signaling of RXFP3 between mammalian and avian species.


Although cRLN3 is able to activate both cRXFP1 and cRXFP3, the potency of cRLN3 for cRXFP1 activation is at least 10-fold higher than that for cRXFP3. Similarly,

rhRLN3 shows a higher potency for cRXFP1 activation (EC<sub>50</sub>: 2.68 nM) than for cRXFP3 (EC<sub>50</sub>: 41.55 nM). The present study supports that chicken RLN3 is a functional analog of rhRLN3. However, our finding contrasts with that of mammalian species. In mammals, as an endogenous ligand for RXFP3, RLN3 shows a higher potency for RXFP3 activation than for RXFP1 (Liu et al., 2005). The difference may result from ligand–receptor interaction model change during evolution (Bathgate et al., 2003; Bathgate et al., 2018).

In addition to the Gs-cAMP signaling pathway, we also found that cRXFP1 activation can increase intracellular Ca<sup>2+</sup> levels (Figure 4B). This finding differs from that in mammals that RXFP1 activation cannot increase Ca<sup>2+</sup> levels (Bani et al., 2002). Like mammalian RXFP3, cRXFP3 cannot activate the Ca<sup>2+</sup> signaling pathway in the present study, thus supporting its conserved signaling properties between birds and mammals (Liu et al., 2003a; Liu et al., 2003b).

# Chicken RLN3 functions as a novel pituitary hormone involving female reproduction

In the present study, *cRLN3* mRNA expression has been detected to be expressed abundantly in the chicken pituitary (Figure 6). Its abundance in our single-cell transcriptome dataset from the pituitary is very high, reaching a level similar to that of the pituitary genes *LHB/FSHB/GRP/ CART*. As the key pituitary hormone in reproduction, LH and FSH are involved in follicular development and ovulation in chickens (Palmer and Bahr, 1992; Oguike et al., 2005). GRP, as a novel "gonadotrophic factor" in chickens (Mo et al., 2017), is reported to be involved in the regulation of reproductive and gastrointestinal activities. CART, expressed abundantly in pituitary cells and regulated by hypothalamic factors CRH and GnRH, is reported to be involved in the regulation of stress and reproductive



Effects of hypothalamic factors (GnRH or CRH) and sex steroid (E2/P4/DHT) treatment on *cRLN3* expression in cultured chicken pituitary cells detected by qPCR. (A) Effects of GnRH (10 nM) or CRH (10 nM) treatment for 4 h, 24 h on *cRLN3* expression in cultured pituitary cells. (B) Effects of GnRH (1, 10, and 100 nM) treatment for 4 h on *cRLN3* expression in cultured pituitary cells. (C) Effects of CRH (0.1, 1, and 10 nM) treatment for 24 h on *cRLN3* expression in cultured pituitary cells. Each data point represents the mean  $\pm$  SEM of four replicates (N = 4). (D) Effects of E2 (100 nM), P4 (100 nM) or DHT (100 nM) treatment for 4 h, 24 h on *cRLN3* expression in cultured pituitary cells. \*, *p* < 0.05 vs. control, \*\*, *p* < 0.005 vs. control, and \*\*\*, *p* < 0.001 vs. control.

behavior in domestic chickens (Mo et al., 2015; Mo et al., 2019). Together with the cell signaling experiments which prove that cRLN3 can be secreted from the chicken pituitary cells (Figure 6C), the present study supports that cRLN3 plays its function as a pituitary hormone. Following the detection that its receptors (*cRXFP1* and *cRXFP3*) are differentially expressed in a wide range of chicken tissues, cRLN3 may, on the one hand, be functional in the brain as a neuropeptide (Smith et al., 2011) in mammals (Bathgate et al., 2002; Burazin et al., 2002; Liu et al., 2003b; Smith et al., 2010) and other species including fish (Donizetti et al., 2008). On the other hand, as a pituitary hormone, cRLN3 may also play a role in the endocrine system, targeting wide tissues and, thus, be involved in a wide range of physiological processes.

In the present study, pituitary cRLN3 mRNA expression was shown to be regulated by the hypothalamic factors GnRH and CRH which further supports cRLN3 to be functional as a pituitary hormone (Figure 7). The present study reveals that CRH potently stimulates the expression of cRLN3 in a doseand time-dependent manner (Figure 7C). In contrast, GnRH could only weakly stimulate the mRNA expression of cRLN3 (Figure 7B). Since GnRH is pulsed secreted and negatively regulated by CRH (Ciechanowska et al., 2010), the expression of RLN3 mRNA may be regulated by CRH. As the key player in hypothalamus-pituitary-adrenal (HPA) axis of the vertebrates, CRH controls multiple physiological processes associated with the HPA axis in birds and mammals (Papadimitriou and Priftis, 2009; Cornett et al., 2013). The RLN3 expression/secretion induced by CRH supports its conserved physiological functions in vertebrates. For example, RLN3 can stimulate rat hypothalamic explants to release GnRH and CRH, and its intraventricular (icv) injection can also increase plasma LH, ACTH, and corticosterone levels (McGowan et al., 2008; McGowan et al., 2014). In chickens, in the transcriptional analyses of newly hatched chicks during fasting and delayed feeding, RLN3 has been identified in a gene network supporting its important role in nutrition (Higgins et al., 2010).

In the present study, the *cRLN3* mRNA expression was shown to be sexually dimorphic with a much higher abundance in the female pituitary and hypothalamus, strongly suggesting its involvement in female reproduction. Supporting evidence also comes from the high expression of its cognate receptor (*cRXFP1*) in chicken tissues. Similar to rats, *RXFP1* is highly expressed in the uterus involving uterine contractions (Hsu et al., 2002; Vodstrcil et al., 2010). In addition, *cRXFP1* is also detected to be expressed highly in a wide range of female tissues (infundibulum, isthmus, uterus, and vagina), thus supporting its role in reproduction. Supporting evidence also comes from steroid hormone feedback regulation. In the present, E2 has been found to increase the expression of cRLN3 (Figure 7D). As a sex steroid hormone, E2 is mainly secreted by the growing follicles and the ovary, which play an important

role in female reproduction, including acting as the growth factor for reproductive organs' growth (Cooke et al., 1998; Cooke et al., 2021), triggering hypothalamic events via a positive feedback system (Micevych et al., 2008; Micevych and Sinchak, 2011), and maintaining follicle growth and maturation (Britt et al., 2004; Drummond, 2006; Padmanabhan et al., 2018). The findings that cRLN3 is involved in female reproductive biology are in line with the report that female teleost fish that RLN3 promotes the production of E2 during follicular development (Wilson et al., 2009; Yang et al., 2020). In another transcriptome analysis between the two divergent chicken breeds, which are in the laying phase and the brooding phase, the expression of RLN3 mRNA shows downregulation in brooding chickens, thus pointing out its role actively involved in reproductive biology (Shen et al., 2016). The report that RLN3 is actively involved in female reproductive biology also comes from the study by Ghanem and Johnson (2021) in a shotgun proteomics study using isobaric tags to characterize the proteins in chicken ovarian follicles immediately before and after cyclic recruitment. RLN3 is revealed to be distinctively expressed in a total of 1,535 proteins. Based on quantitative PCR, the expression of RLN3 and its receptors were further revealed to be expressed abundantly in granulosa cells and the theca cells, thus implicating the important role of RLN3 in chicken female reproductive biology.

Till present, a total of five genes (LHB, FSHB, GRP, CART, and RLN3) have been detected to be abundantly expressed in chicken pituitary gonadotrope cells (Mo et al., 2017; Zhang et al., 2021). Although these genes concentrate on the same cell cluster, these genes vary in sexual distribution patterns, cell co-localization profiles, and the hypothalamus regulation networks. For example, RLN3 and GRP show an abundance in female gonadotrope cells while LHB, FSHB, and CART show a higher expression in male pituitary cells. In addition, all cells expressing RLN3 overlap with the cells expressing LHB and GRP. In contrast, the cells expressing RLN3 only partially colocalize with the cells expressing FSHB and CART (Zhang et al., 2021). At the hypothalamus regulation level, RLN3 is mainly regulated by CRH while CART is regulated by the GnRH and CRH with equal potency (Cai et al., 2015; Mo et al., 2015; Mo et al., 2019). The present study supports that these genes play differential roles in chicken pituitary function. With their especially complicated regulation networks reported in chickens, the present study enriches our understanding of avian pituitary biology, thus shedding light on their function across species.

In summary, we identified a relaxin peptide (cRLN3) and its two receptors (cRXFP1 and cRXFP3) in chickens. Functional studies have shown that cRLN3 can activate cRXFP1 and cRXFP3, and cRXFP1 is a cognate receptor for cRLN3. Tissue distribution analyses show that *cRLN3* is highly expressed in the female chicken pituitary. Moreover, *cRLN3* in pituitary cells is regulated by hypothalamic factors GnRH and CRH and sex steroid hormone E2. These results suggest that cRLN3 is a novel hormone from the pituitary, which is associated with female reproduction in birds. Undoubtedly, these findings will help us to better understand the structure, ligand-receptor binding, and physiological functions of the relaxin system in birds and other vertebrates.

### Data availability statement

Publicly available datasets were analyzed in this study. The scRNA-seq data used in this study have been deposited in the Genome Sequence Archive in the National Genomics Data Center, China National Center for Bioinformation/Beijing Institute of Genomics, Chinese Academy of Sciences, under accession number CRA003604 and are publicly accessible at https://ngdc.cncb.ac.cn/gsa/. A supplementary online web server (https://scrna.avianscu.com/pit/) was developed to facilitate the use of this dataset.

# **Ethics statement**

The animal study was reviewed and approved by the Animal Ethics Committee of Sichuan University (Chengdu, China).

### Author contributions

Conceptualization: CL, JL, and YW; formal analysis: HZ and BJ; funding acquisition: JZ, JL, and YW; investigation: CL and

### References

Bani, D., Baronti, R., Vannacci, A., Bigazzi, M., Sacchi, T. B., Mannaioni, P. F., et al. (2002). Inhibitory effects of relaxin on human basophils activated by stimulation of the Fcc receptor. The role of nitric oxide. *Int. Immunopharmacol.* 2 (8), 1195–1204. doi:10.1016/S1567-5769(02) 00079-6

Bathgate, R. A. D., Kocan, M., Scott, D. J., Hossain, M. A., Good, S. V., Yegorov, S., et al. (2018). The relaxin receptor as a therapeutic target - perspectives from evolution and drug targeting. *Pharmacol. Ther.* 187, 114–132. doi:10.1016/j. pharmthera.2018.02.008

Bathgate, R. A. D., Samuel, C. S., Burazin, T. C. D., Gundlach, A. L., and Tregear, G. W. (2003). Relaxin: new peptides, receptors and novel actions. *Trends Endocrinol. Metab.* 14 (5), 207–213. doi:10.1016/s1043-2760(03) 00081-x

Bathgate, R. A., Halls, M. L., van der Westhuizen, E. T., Callander, G. E., Kocan, M., and Summers, R. J. (2013). Relaxin family peptides and their receptors. *Physiol. Rev.* 93 (1), 405–480. doi:10.1152/physrev.00001.2012

Bathgate, R. A., Ivell, R., Sanborn, B. M., Sherwood, O. D., and Summers, R. J. (2006). International union of pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. *Pharmacol. Rev.* 58 (1), 7–31. doi:10.1124/pr.58.1.9

Bathgate, R. A., Samuel, C. S., Burazin, T. C., Layfield, S., Claasz, A. A., Reytomas, I. G., et al. (2002). Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene. Novel members of the relaxin peptide family. *J. Biol. Chem.* 277 (2), 1148–1157. doi:10.1074/jbc.M107882200

Brackett, K. H., Fields, P. A., Dubois, W., Chang, S. M., Mather, F. B., and Fields, M. J. (1997). Relaxin: an ovarian hormone in an avian species (*Gallus domesticus*). *Gen. Comp. Endocrinol.* 105 (2), 155–163. doi:10.1006/gcen.1996. 6819

HZ; methodology: CL, BJ, and XZ; supervision: YW; and writing-review and editing: JZ, YW, and JL.

### Funding

This work was supported by grants from the National Natural Science Foundation of China (U1901206, 32072706, and 31802056), the Sichuan University Postdoctoral Interdisciplinary Innovation Start-up Fund (0020404153033), and the Sichuan University Postdoctoral Research and Development Fund (2021SCU12101).

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Britt, K. L., Saunders, P. K., McPherson, S. J., Misso, M. L., Simpson, E. R., and Findlay, J. K. (2004). Estrogen actions on follicle formation and early follicle development. *Biol. Reprod.* 71 (5), 1712–1723. doi:10.1095/biolreprod.104.028175

Burazin, T. C., Bathgate, R. A., Macris, M., Layfield, S., Gundlach, A. L., and Tregear, G. W. (2002). Restricted, but abundant, expression of the novel rat gene-3 (R3) relaxin in the dorsal tegmental region of brain. *J. Neurochem.* 82 (6), 1553–1557. doi:10.1046/j.1471-4159.2002.01114.x

Cai, G., Mo, C., Huang, L., Li, J., and Wang, Y. (2015). Characterization of the two CART genes (CART1 and CART2) in chickens (Gallus gallus). *PLoS One* 10 (5), e0127107. doi:10.1371/journal.pone.0127107

Calvez, J., de Avila, C., Matte, L. O., Guevremont, G., Gundlach, A. L., and Timofeeva, E. (2016). Role of relaxin-3/RXFP3 system in stress-induced binge-like eating in female rats. *Neuropharmacology* 102, 207–215. doi:10.1016/j.neuropharm. 2015.11.014

Ciechanowska, M., Łapot, M., Mateusiak, K., and Przekop, F. (2010). Neuroendocrine regulation of GnRH release and expression of GnRH and GnRH receptor genes in the hypothalamus-pituitary unit in different physiological states. *Reprod. Biol.* 10 (2), 85–124. doi:10.1016/s1642-431x(12) 60054-0

Cooke, P. S., Buchanan, D. L., Lubahn, D. B., and Cunha, G. R. (1998). Mechanism of estrogen action: lessons from the estrogen receptor-a knockout mouse. *Biol. Reprod.* 59 (3), 470–475. doi:10.1095/biolreprod59.3.470

Cooke, P. S., Mesa, A. M., Sirohi, V. K., and Levin, E. R. (2021). Role of nuclear and membrane estrogen signaling pathways in the male and female reproductive tract. *Differentiation*. 118, 24–33. doi:10.1016/j.diff.2020.11.002

Cornett, L. E., Kang, S. W., and Kuenzel, W. J. (2013). A possible mechanism contributing to the synergistic action of vasotocin (VT) and corticotropin-releasing

hormone (CRH) receptors on corticosterone release in birds. Gen. Comp. Endocrinol. 188, 46-53. doi:10.1016/j.ygcen.2013.02.032

Crawford, R., Hudson, P., Shine, J., Niall, H., Eddy, R., and Shows, T. (1984). Two human relaxin genes are on chromosome 9. *EMBO J* 3 (10), 2341–2345. doi:10. 1002/j.1460-2075.1984.tb02136.x

Donizetti, A., Grossi, M., Pariante, P., D'Aniello, E., Izzo, G., Minucci, S., et al. (2008). Two neuron clusters in the stem of postembryonic zebrafish brain specifically express relaxin-3 gene: first evidence of nucleus incertus in fish. *Dev. Dyn.* 237 (12), 3864–3869. doi:10.1002/dvdy.21786

Drummond, A. E. (2006). The role of steroids in follicular growth. Reprod. Biol. Endocrinol. 4 (1), 16-11. doi:10.1186/1477-7827-4-16

Fevold, H. L., Hisaw, F. L., and Meyer, R. K. (1930). The relaxative hormone of the corpus luteum. Its purification and Concentration1. *J. Am. Chem. Soc.* 52 (8), 3340–3348. doi:10.1021/ja01371a051

Ghanem, K., and Johnson, A. L. (2021). Proteome profiling of chicken ovarian follicles immediately before and after cyclic recruitment. *Mol. Reprod. Dev.* 88 (8), 571–583. doi:10.1002/mrd.23522

Good, S., Yegorov, S., Martijn, J., Franck, J., and Bogerd, J. (2012). New insights into ligand-receptor pairing and coevolution of relaxin family peptides and their receptors in teleosts. *Int. J. Evol. Biol.* 2012, 310278. doi:10.1155/2012/310278

Haley, J., Hudson, P., Scanlon, D., John, M., Cronk, M., Shine, J., et al. (1982). Porcine relaxin: Molecular cloning and cDNA structure. *DNA* 1 (2), 155–162. doi:10.1089/dna.1.1982.1.155

Halls, M. L., Bathgate, R. A., and Summers, R. J. (2007). Comparison of signaling pathways activated by the relaxin family peptide receptors, RXFP1 and RXFP2, using reporter genes. *J. Pharmacol. Exp. Ther.* 320 (1), 281–290. doi:10.1124/jpet. 106.113225

Halls, M. L., Bathgate, R. A., and Summers, R. J. (2006). Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms. *Mol. Pharmacol.* 70 (1), 214–226. doi:10.1124/mol.105.021691

Halls, M. L., Bond, C. P., Sudo, S., Jin, K., Ferraro, T., Layfield, S., et al. (2005). Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8). *J. Pharmacol. Exp. Ther.* 313 (2), 677–687. doi:10.1124/jpet.104.080655

Halls, M. L., Hewitson, T. D., Moore, X. L., Du, X. J., Bathgate, R. A., and Summers, R. J. (2009). Relaxin activates multiple cAMP signaling pathway profiles in different target cells. *Ann. N. Y. Acad. Sci.* 1160, 108–111. doi:10.1111/j.1749-6632.2008.03814.x

Higgins, S. E., Ellestad, L. E., Trakooljul, N., McCarthy, F., Saliba, J., Cogburn, L. A., et al. (2010). Transcriptional and pathway analysis in the hypothalamus of newly hatched chicks during fasting and delayed feeding. *BMC Genomics* 11, 162. doi:10. 1186/1471-2164-11-162

Hopkins, E. J., Layfield, S., Ferraro, T., Bathgate, R. A. D., and Gooley, P. R. (2006). The NMR solution structure of the relaxin (RXFP1) receptor lipoprotein receptor class A module and identification of key residues in the N-terminal region of the module that mediate receptor activation. *J. Biol. Chem.* 282 (6), 4172–4184. doi:10.1074/jbc.M609526200

Hsu, S. Y., Nakabayashi, K., Nishi, S., Kumagai, J., Kudo, M., Sherwood, O. D., et al. (2002). Activation of orphan receptors by the hormone relaxin. *Science* 295 (5555), 671–674. doi:10.1126/science.1065654

Hsu, S. Y. T., Nakabayashi, K., Nishi, S., Kumagai, J., Kudo, M., Bathgate, R. A. D., et al. (2003). Relaxin signaling in reproductive tissues. *Mol. Cell. Endocrinol.* 202 (1-2), 165–170. doi:10.1016/s0303-7207(03)00078-9

Hudson, P., Haley, J., John, M., Cronk, M., Crawford, R., Haralambidis, J., et al. (1983). Structure of a genomic clone encoding biologically active human relaxin. *Nature* 301 (5901), 628–631. doi:10.1038/301628a0

Jiang, B., Cao, B., Zhou, Z., Li, Z., Lv, C., Zhang, J., et al. (2022). Characterization of chicken a2a-adrenoceptor: Molecular cloning, functional analysis, and its involvement in ovarian follicular development. *Genes* 13 (7), 1113. doi:10.3390/genes13071113

Joseph, N. T., Morgan, K., Sellar, R., McBride, D., Millar, R. P., and Dunn, I. C. (2009). The chicken type III GnRH receptor homologue is predominantly expressed in the pituitary, and exhibits similar ligand selectivity to the type I receptor. *J. Endocrinol.* 202 (1), 179–190. doi:10.1677/JOE-08-0544

Kocan, M., Sarwar, M., Hossain, M. A., Wade, J. D., and Summers, R. J. (2014). Signalling profiles of H3 relaxin, H2 relaxin and R3(B∆23-27)R/15 acting at the relaxin family peptide receptor 3 (RXFP3). Br. J. Pharmacol. 171 (11), 2827–2841. doi:10.1111/bph.12623

Kumagai, J., Hsu, S. Y., Matsumi, H., Roh, J. S., Fu, P., Wade, J. D., et al. (2002). INSL3/Leydig insulin-like peptide activates the LGR8 receptor important in testis descent. *J. Biol. Chem.* 277 (35), 31283-31286. doi:10. 1074/jbc.C200398200

Liu, C., Chen, J., Kuei, C., Sutton, S., Nepomuceno, D., Bonaventure, P., et al. (2005). Relaxin-3/insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeatcontaining G protein-coupled receptor 7. *Mol. Pharmacol.* 67 (1), 231–240. doi:10.1124/mol.104.006700

Liu, C., Chen, J., Sutton, S., Roland, B., Kuei, C., Farmer, N., et al. (2003a). Identification of relaxin-3/INSL7 as a ligand for GPCR142. *J. Biol. Chem.* 278 (50), 50765–50770. doi:10.1074/jbc.M308996200

Liu, C., Eriste, E., Sutton, S., Chen, J., Roland, B., Kuei, C., et al. (2003b). Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. *J. Biol. Chem.* 278 (50), 50754–50764. doi:10.1074/jbc.M308995200

Liu, H., Luo, Q., Zhang, J., Mo, C., Wang, Y., and Li, J. (2019). Endothelins (EDN1, EDN2, EDN3) and their receptors (EDNRA, EDNRB, EDNRB2) in chickens: Functional analysis and tissue distribution. *Gen. Comp. Endocrinol.* 283, 113231. doi:10.1016/j.ygcen.2019.113231

Liu, M., Bu, G., Wan, Y., Zhang, J., Mo, C., Li, J., et al. (2022). Evidence for neuropeptide W acting as a physiological corticotropin-releasing inhibitory factor in male chickens. *Endocrinology* 163 (7), bqac073. doi:10.1210/endocr/bqac073

McGowan, B. M., Minnion, J. S., Murphy, K. G., Roy, D., Stanley, S. A., Dhillo, W. S., et al. (2014). Relaxin-3 stimulates the neuro-endocrine stress axis via corticotrophin-releasing hormone. *J. Endocrinol.* 221 (2), 337–346. doi:10.1530/JOE-13-0603

McGowan, B. M., Stanley, S. A., Donovan, J., Thompson, E. L., Patterson, M., Semjonous, N. M., et al. (2008). Relaxin-3 stimulates the hypothalamic-pituitary-gonadal axis. *Am. J. Physiol. Endocrinol. Metab.* 295 (2), E278–E286. doi:10.1152/ajpendo.00028.2008

Micevych, P., and Sinchak, K. (2011). The neurosteroid progesterone underlies estrogen positive feedback of the LH surge. *Front. Endocrinol.* 2, 90. doi:10.3389/ fendo.2011.00090

Micevych, P., Soma, K. K., and Sinchak, K. (2008). Neuroprogesterone: Key to estrogen positive feedback? *Brain Res. Rev.* 57 (2), 470–480. doi:10.1016/j. brainresrev.2007.06.009

Mo, C., Cai, G., Huang, L., Deng, Q., Lin, D., Cui, L., et al. (2015). Corticotropinreleasing hormone (CRH) stimulates cocaine- and amphetamine-regulated transcript gene (CART1) expression through CRH type 1 receptor (CRHR1) in chicken anterior pituitary. *Mol. Cell. Endocrinol.* 417, 166–177. doi:10.1016/j.mce. 2015.09.007

Mo, C., Huang, L., Cui, L., Lv, C., Lin, D., Song, L., et al. (2017). Characterization of NMB, GRP and their receptors (BRS3, NMBR and GRPR) in chickens. *J. Mol. Endocrinol.* 59 (1), 61–79. doi:10.1530/JME-17-0020

Mo, C., Lv, C., Huang, L., Li, Z., Zhang, J., Li, J., et al. (2019). Regulation of pituitary cocaine- and amphetamine-regulated transcript expression and secretion by hypothalamic gonadotropin-releasing hormone in chickens. *Front. Physiol.* 10, 882. doi:10.3389/fphys.2019.00882

Oguike, M. A., Igboeli, G., Ibe, S. N., and Ironkwe, M. O. (2005). Physiological and endocrinological mechanisms associated with ovulatory cycle and inducedmoulting in the domestic chicken—a review. *Worlds Poult. Sci. J.* 61 (4), 625–632. doi:10.1079/wps200574

Padmanabhan, V., Puttabyatappa, M., and Cardoso, R. C. (2018). "Hypothalamus-pituitary-ovary Axis," in *Encyclopedia of reproduction*, Netherlands: Elsevier. 121-129. doi:10.1016/B978-0-12-801238-3.64632-9

Palmer, S. S., and Bahr, J. M. J. B. P. (1992). Follicle stimulating hormone increases serum oestradiol-17 beta concentrations, number of growing follicles and yolk deposition in aging hens (*Gallus gallus* domesticus) with decreased egg production. *Br. Poult. Sci.* 33 (2), 403–414. doi:10.1080/00071669208417478

Papadimitriou, A., and Priftis, K. N. (2009). Regulation of the hypothalamicpituitary-adrenal axis. *Neuroimmunomodulation* 16 (5), 265–271. doi:10.1159/ 000216184

Patil, N. A., Rosengren, K. J., Separovic, F., Wade, J. D., Bathgate, R. A. D., and Hossain, M. A. (2017). Relaxin family peptides: structure-activity relationship studies. *Br. J. Pharmacol.* 174 (10), 950–961. doi:10.1111/bph.13684

Ryan, P. J., Kastman, H. E., Krstew, E. V., Rosengren, K. J., Hossain, M. A., Churilov, L., et al. (2013). Relaxin-3/RXFP3 system regulates alcohol-seeking. *Proc. Natl. Acad. Sci. U. S. A.* 110 (51), 20789–20794. doi:10.1073/pnas.1317807110

Scott, D. J., Layfield, S., Yan, Y., Sudo, S., Hsueh, A. J., Tregear, G. W., et al. (2006). Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is mediated by their unique low density lipoprotein class A modules. *J. Biol. Chem.* 281 (46), 34942–34954. doi:10.1074/jbc. M602728200

Shen, X., Bai, X., Xu, J., Zhou, M., Xu, H., Nie, Q., et al. (2016). Transcriptome sequencing reveals genetic mechanisms underlying the transition between the laying and brooding phases and gene expression changes associated with

divergent reproductive phenotypes in chickens. Mol. Biol. Rep. 43 (9), 977-989. doi:10.1007/s11033-016-4033-8

Shimizu, M., and Bédécarrats, G. Y. (2006). Identification of a novel pituitaryspecific chicken gonadotropin-releasing hormone receptor and its splice variants. *Biol. Reprod.* 75 (5), 800–808. doi:10.1095/biolreprod.105.050252

Smith, C. M., Chua, B. E., Zhang, C., Walker, A. W., Haidar, M., Hawkes, D., et al. (2014). Central injection of relaxin-3 receptor (RXFP3) antagonist peptides reduces motivated food seeking and consumption in C57BL/6J mice. *Behav. Brain Res.* 268, 117–126. doi:10.1016/j.bbr.2014.03.037

Smith, C. M., Ryan, P. J., Hosken, I. T., Ma, S., and Gundlach, A. L. (2011). Relaxin-3 systems in the brain-the first 10 years. *J. Chem. Neuroanat.* 42 (4), 262–275. doi:10.1016/j.jchemneu.2011.05.013

Smith, C. M., Shen, P. J., Banerjee, A., Bonaventure, P., Ma, S., Bathgate, R. A., et al. (2010). Distribution of relaxin-3 and RXFP3 within arousal, stress, affective, and cognitive circuits of mouse brain. *J. Comp. Neurol.* 518 (19), 4016–4045. doi:10.1002/cne.22442

Sudo, S., Kumagai, J., Nishi, S., Layfield, S., Ferraro, T., Bathgate, R. A., et al. (2003). H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2. *J. Biol. Chem.* 278 (10), 7855–7862. doi:10.1074/jbc.M212457200

Sun, C., Qiu, Y., Ren, Q., Zhang, X., Cao, B., Zou, Y., et al. (2021). Molecular cloning and functional characterization of three 5-HT receptor genes (HTRIB, HTR1E, and HTR1F) in chickens. *Genes* 12 (6), 891. doi:10.3390/genes12060891

van der Westhuizen, E. T., Christopoulos, A., Sexton, P. M., Wade, J. D., and Summers, R. J. (2010). H2 relaxin is a biased ligand relative to H3 relaxin at the relaxin family peptide receptor 3 (RXFP3). *Mol. Pharmacol.* 77 (5), 759–772. doi:10. 1124/mol.109.061432

van der Westhuizen, E. T., Halls, M. L., Samuel, C. S., Bathgate, R. A., Unemori, E. N., Sutton, S. W., et al. (2008). Relaxin family peptide receptors-from orphans to therapeutic targets. *Drug Discov. Today* 13 (15-16), 640–651. doi:10.1016/j.drudis. 2008.04.002

van der Westhuizen, E. T., Werry, T. D., Sexton, P. M., and Summers, R. J. (2007). The relaxin family peptide receptor 3 activates extracellular signal-regulated kinase 1/2 through a protein kinase C-dependent mechanism. *Mol. Pharmacol.* 71 (6), 1618–1629. doi:10.1124/mol.106.032763

Vodstrcil, L. A., Shynlova, O., Verlander, J. W., Wlodek, M. E., and Parry, L. J. (2010). Decreased expression of the rat myometrial relaxin receptor (RXFP1) in late pregnancy is partially mediated by the presence of the conceptus. *Biol. Reprod.* 83 (5), 818–824. doi:10.1095/biolreprod.110.083931

Wilkinson, T. N., Speed, T. P., Tregear, G. W., and Bathgate, R. A. (2005). Evolution of the relaxin-like peptide family. *BMC Evol. Biol.* 5, 14. doi:10.1186/ 1471-2148-5-14

Wilson, B. C., Burnett, D., Rappaport, R., Parry, L. J., and Fletcher, E. K. (2009). Relaxin-3 and RXFP3 expression, and steroidogenic actions in the ovary of teleost fish. *Comp. Biochem. Physiol. A Mol. Integr. Physiol.* 153 (1), 69–74. doi:10.1016/j. cbpa.2008.09.020

Yang, L., Li, Y., Wu, Y., Sun, S., Song, Q., Wei, J., et al. (2020). Rln3a is a prerequisite for spermatogenesis and fertility in male fish. *J. Steroid Biochem. Mol. Biol.* 197, 105517. doi:10.1016/j.jsbmb.2019.105517

Ye, P., Ge, K., Li, M., Yang, L., Jin, S., Zhang, C., et al. (2019). Egg-laying and brooding stage-specific hormonal response and transcriptional regulation in pituitary of Muscovy duck (*Cairina moschata*). *Poult. Sci.* 98 (11), 5287–5296. doi:10.3382/ps/pez433

Yegorov, S., Bogerd, J., and Good, S. V. (2014). The relaxin family peptide receptors and their ligands: new developments and paradigms in the evolution from jawless fish to mammals. *Gen. Comp. Endocrinol.* 209, 93–105. doi:10.1016/j.ygcen. 2014.07.014

Yegorov, S., and Good, S. (2012). Using paleogenomics to study the evolution of gene families: origin and duplication history of the relaxin family hormones and their receptors. *PLoS One* 7 (3), e32923. doi:10.1371/journal.pone.0032923

Zhang, J., Lv, C., Mo, C., Liu, M., Wan, Y., Li, J., et al. (2021). Single-cell RNA sequencing analysis of chicken anterior pituitary: A bird's-eye view on vertebrate pituitary. *Front. Physiol.* 12, 562817. doi:10.3389/fphys.2021. 562817